Conjugates of chemotherapeutic drugs and tissue-binding small molecules, compositions and methods thereof

By locally injecting novel small molecule compounds conjugates with tissue protein binders, targeted delivery and slow release in cancer treatment have been achieved, solving the problems of severe side effects and poor compliance of chemotherapy drugs, and improving treatment efficacy and safety.

CN118946569APending Publication Date: 2024-11-12CANWELL BIOTECH LTD
View PDF 4 Cites 0 Cited by

Patent Information

Application Number
CN202380029671.8
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Priority Date
2022-02-08
Filing Date
2023-02-03
Publication Date
2024-11-12

AI Technical Summary

Technical Problem

Existing chemotherapy drugs have problems such as significant side effects, poor patient compliance, and high hospital costs when treating cancer. In addition, traditional chemotherapy requires frequent intravenous injections, which affects patient compliance.

Method used

A novel small molecule compound conjugate with a tissue protein binder has been developed to deliver drugs to solid tumors via local injection. The conjugate allows for the slow release of the small molecule drug, reducing systemic exposure and minimizing side effects.

Benefits of technology

This technology enables sustained drug release within solid tumors, enhancing tumor eradication while reducing systemic reactions, thus improving the safety and effectiveness of treatment.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure BDA0005055464420000011
    Figure BDA0005055464420000011
  • Figure BDA0005055464420000021
    Figure BDA0005055464420000021
  • Figure BDA0005055464420000031
    Figure BDA0005055464420000031
Patent Text Reader

Abstract

Disclosed are novel conjugates of tissue-binding small molecules and therapeutic agents and pharmaceutical compositions thereof, as well as their use and methods in the treatment of certain diseases or disorders, such as cancer.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention generally relates to novel compounds and their therapeutic applications. More specifically, the present invention provides a conjugate of a tissue-binding small molecule and a therapeutic agent (e.g., an anticancer agent) and a pharmaceutical composition thereof, as well as their uses and methods in treating certain diseases or disorders (e.g., cancer). Background Art

[0002] Immunotherapy, which treats disease by activating or suppressing a patient's immune system, has attracted considerable interest from researchers and clinicians over the past decade, particularly because of its promise to treat a variety of cancers. (Syn, et al. 2017 The Lancet Oncol. 18(12): e731-e741; Conforti L 2012 Clin. Immunol. 142(2): 105-106; Nishino, et al. 2017 Nat. Rev. Clin. Oncol. 14(11): 655-668).) In order to improve the therapeutic effect, immunotherapy needs to be combined with small molecule drugs, such as chemotherapeutic drugs, kinase inhibitors, indoleamine-2,3-dioxygenase 1 (IDO-1) and adenosine receptor inhibitor (A2a) inhibitors, chemokine receptor antagonists, toll-like receptors (TLRs) and interferon gene stimulator (STING) regulators (Huck, et al. 2018 Angew Chem. Int. Ed. 57, 4412-4428.).

[0003] Small molecule chemotherapy drugs remain an important part of conventional cancer treatment and can be combined with surgery, radiotherapy and immunotherapy to improve clinical outcomes. The challenge facing traditional chemotherapy is to reduce or eliminate side effects and damage caused by systemic exposure while retaining efficacy. In addition, some drugs require frequent administration via intravenous injection or infusion for several hours. This may lead to increased patient compliance and related hospital costs.

[0004] Therefore, new cancer therapies are needed, particularly those that are safe and effective. Summary of the invention

[0005] The present invention is based in part on the unexpected discovery of novel small molecule compounds, methods of synthesizing the same, pharmaceutical compositions and methods of using the same for treating or alleviating various diseases or disorders

[0006] In one aspect, the present invention generally relates to a compound represented by the following formula: wherein X is CHR or NR, and R is H or alkyl; wherein n is an integer selected from 2-8 (i.e., 2, 3, 4, 5, 6, 7 or 8), wherein n is an integer selected from 2-10 (e.g., 2, 3, 4, 5, 6, 7, 8, 9 or 10), Where R 2 is H or P(=O)(R 3 )2,R 3 is an alkyl group, L is a single bond or is selected from the following groups: k is an integer selected from 0-4 (e.g., 0, 1, 2, 3 or 4); Where R 2 is H or (=O)(R 3 )2,R 3 is an alkyl group, and L is a single bond or a group selected from the following: k is an integer selected from 0-4 (e.g., 0, 1, 2, 3 or 4); or a pharmaceutically acceptable form or isotopic derivative thereof.

[0007] In another aspect, the present invention generally relates to a pharmaceutical composition comprising a compound disclosed in the present application and a pharmaceutically acceptable excipient or carrier, diluent.

[0008] In another aspect, the present invention generally relates to a unit dosage form comprising a pharmaceutical composition comprising a compound disclosed herein.

[0009] In another aspect, the present invention generally relates to a method for treating or alleviating a disease or disorder, comprising administering to a subject in need thereof a pharmaceutical composition comprising a compound disclosed herein and a pharmaceutically acceptable excipient or carrier, diluent.

[0010] In another aspect, the present invention generally relates to a use comprising using a compound disclosed herein to treat or alleviate a disease or disorder.

[0011] In another aspect, the present invention generally relates to a use for preparing a drug for treating or alleviating a disease or disorder, comprising using a compound disclosed in the present application and a pharmaceutically acceptable excipient or carrier, diluent. definition

[0012] Unless otherwise defined, technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention belongs. General principles of organic chemistry, as well as specific functional moieties and reactivities, are described in Organic Chemistry (Thomas Sorrell, University Science Books, Sausalito: 1999) and March's Advanced Organic Chemistry 5 th Ed.: Smith, MB and March, J., John Wiley & Sons, New York: 2001), the entire contents of which are incorporated herein by reference.

[0013] Certain compounds of the present invention may exist in specific geometric or stereoisomeric forms. Compounds contemplated by the present invention include cis and trans isomers, R- and S-enantiomers, diastereomers, (d)-isomers, (l)-isomers, racemic mixtures thereof and other mixtures, which fall within the scope of the present invention. Additional asymmetric carbon atoms may be present in substituents, such as alkyl. All of these isomers and mixtures thereof are included in the present invention.

[0014] Isomeric mixtures containing various isomer ratios can be used according to the present invention. For example, in the case of only two isomers combined, the mixtures discussed in the present invention contain isomer ratios of 50:50, 60:40, 70:30, 80:20, 90:10, 95:5, 96:4, 97:3, 98:2, 99:1 or 100:0. It will be understood by those skilled in the art that similar ratios are contemplated for more complex isomer mixtures.

[0015] For example, if a specific enantiomer of a compound of the invention is desired, it can be prepared by asymmetric synthesis or by using a chiral auxiliary derivative, separating the resulting diastereomeric mixture, and cleaving the auxiliary group to obtain the pure desired enantiomer. Alternatively, when the molecule contains a basic functional group (such as an amino group) or an acidic functional group (such as a carboxyl group), diastereomeric salts are formed with a suitable optically active acid or base, followed by separation of the formed diastereomers by fractional crystallization or chromatography as is well known in the art, and then the pure enantiomer is recovered.

[0016] Solvates and polymorphs of the compounds described herein are also contemplated herein. Solvates of the compounds described herein include, for example, hydrates.

[0017] The term "inhibition" herein refers to a measurable decrease in biological activity. Thus, "inhibition" or "inhibitory effect" herein may be a percentage of normal activity levels.

[0018] As used herein, the term "effective amount" of an active agent refers to an amount sufficient to induce a desired biological response. As will be appreciated by those of ordinary skill in the art, the effective amount of a compound of the invention may vary depending on factors such as the desired biological endpoint, the pharmacokinetics of the compound, the disease being treated, the mode of administration, and the patient.

[0019] As used herein, "therapy" or "treatment" of a disease or disorder refers to a method of alleviating, delaying or ameliorating the condition before or after the disease or disorder occurs. Treatment may be for one or more effects or symptoms of the disease and / or underlying pathology. Treatment may be alleviation, and may be, but is not limited to, complete regression of the disease or disease symptoms. Such alleviation or prevention may be at least 5%, 10%, 20%, 40%, 50%, 60%, 80%, 90%, 95% or 100% as measured by various standard techniques compared to an equivalent untreated control group.

[0020] As used herein, "pharmaceutically acceptable forms" of disclosed compounds include, but are not limited to, pharmaceutically acceptable salts, hydrates, esters, solvates, polymorphs, isomers, prodrugs, and isotopically labeled derivatives of disclosed compounds. In one embodiment, "pharmaceutically acceptable forms" include, but are not limited to, pharmaceutically acceptable salts, esters, prodrugs, and isotopically labeled derivatives of disclosed compounds. In some embodiments, "pharmaceutically acceptable forms" include, but are not limited to, pharmaceutically acceptable isomers, stereoisomers, prodrugs, and isotopically labeled derivatives of disclosed compounds.

[0021] In some embodiments, the pharmaceutically acceptable form is a pharmaceutically acceptable salt. As used herein, the term "pharmaceutically acceptable salt" refers to a salt that is suitable for contact with the tissue of a subject without producing excessive toxicity, irritation, allergic reaction, etc., within the scope of reasonable medical judgment, and is commensurate with a reasonable benefit / risk ratio. Pharmaceutically acceptable salts are well known in the art. For example, Berge et al., in Pharmaceutical Science (1977) 66: 1-19, describe pharmaceutically acceptable salts in detail. Pharmaceutically acceptable salts of the compounds provided herein include those derived from appropriate inorganic and organic acids and bases. Examples of pharmaceutically acceptable non-toxic acid addition salts are amino salts formed by inorganic acids such as hydrochloric acid, hydrobromic acid, phosphoric acid, sulfuric acid and perchloric acid or organic acids such as acetic acid, oxalic acid, maleic acid, tartaric acid, citric acid, succinic acid or malonic acid, or by using other methods in the art, such as amino salts formed by ion exchange. Other pharmaceutically acceptable salts include adipate, alginate, ascorbate, aspartate, benzenesulfonic acid, benzenesulfonate, benzoate, bisulfate, borate, butyrate, camphorate, camphorsulfonate, citrate, cyclopentanepropionate, digluconate, dodecylsulfate, ethanesulfonate, formate, fumarate, gluconate, glycerophosphate, gluconate, hemisulfate, heptanoate, hexanoate, hydroiodide, 2-hydroxy-ethanesulfonate, lactobionate, laurate, dodecylsulfate, malate, maleate, malonate, methanesulfonate, 2-naphthalenesulfonate, nicotinate, nitrate, oleate, oxalate, palmitate, pamoate, pectinate, persulfate, 3-phenylpropionate, phosphate, picrate, pivalate, propionate, stearate, succinate, sulfate, tartrate, thiocyanate, p-toluenesulfonate, undecanoate, valerate, and the like. In some embodiments, organic acids from which salts can be derived include, for example, acetic acid, propionic acid, glycolic acid, pyruvic acid, oxalic acid, lactic acid, trifluoroacetic acid, maleic acid, malonic acid, succinic acid, fumaric acid, tartaric acid, citric acid, benzoic acid, cinnamic acid, mandelic acid, methanesulfonic acid, ethanesulfonic acid, p-toluenesulfonic acid, salicylic acid, and the like.

[0022] The salts can be prepared in situ during the isolation and purification of the disclosed compounds, or separately, for example, by reacting the free base or free acid of the parent compound with a suitable base or acid, respectively. Pharmaceutically acceptable salts derived from appropriate bases include alkali metal, alkaline earth metal, ammonium and N + (C 1-4 alkyl) 4Salt. Representative alkali metal or alkaline earth metal salts include sodium, lithium, potassium, calcium, magnesium, iron, zinc, copper, manganese, aluminum, etc. Other pharmaceutically acceptable salts include non-toxic ammonium, quaternary ammonium and primary amine cations, which are formed by counterions such as halides, hydroxides, carboxylates, sulfates, phosphates, nitrates, lower alkyl sulfonates and aryl sulfonates. Organic bases from which salts can be derived include, for example, primary amines, secondary amines and tertiary amines, substituted amines, including naturally occurring substituted amines, cyclic amines, basic ion exchange resins, etc., such as isopropylamine, trimethylamine, diethylamine, triethylamine, tripropylamine and ethanolamine. In certain embodiments, pharmaceutically acceptable base addition salts can be selected from ammonium salts, potassium salts, sodium salts, calcium salts and magnesium salts.

[0023] In some embodiments, the pharmaceutically acceptable form is a "solvate" (e.g., a hydrate). As used herein, the term "solvate" refers to a compound that further includes a stoichiometric or non-stoichiometric amount of a solvent bound by non-covalent intermolecular forces. The solvate can be a disclosed compound or a pharmaceutically acceptable salt thereof. When the solvent is water, the solvate is a "hydrate". Pharmaceutically acceptable solvates and hydrates are complexes that may include, for example, about 1 to 100, 1 to 10, 1 to 2, 3, or 4 solvent or water molecules. It should be understood that the term "compound" used herein includes compounds and solvates of compounds, and mixtures thereof.

[0024] In some embodiments, the pharmaceutically acceptable form is a prodrug. As used herein, the term "prodrug" (or "prodrug") refers to a compound that is converted in vivo to produce a compound disclosed herein or a pharmaceutically acceptable form of the compound. The prodrug is inactive when administered to a subject, but can be converted into an active compound in vivo by hydrolysis (e.g., hydrolysis in the blood). In some cases, the prodrug has better physical and / or transport properties than the parent compound. When administered to a subject, the prodrug can increase the bioavailability of the compound (e.g., by enhancing blood absorption through oral administration), which improves the transport efficiency to the target biological compartment (e.g., the brain or lymphatic system) relative to the parent compound. Relative to the parent compound, exemplary prodrugs include derivatives of the disclosed compounds that have strong water solubility or active transport across the intestinal membrane.

[0025] Prodrug compounds often have advantages in solubility, tissue compatibility or delayed release in mammalian organisms (see Bundgard, H., Design of Prodrugs (1985), pp. 7-9, 21-24 (Elsevier, Amsterdam). Discussions of prodrugs are provided in Prodrugs: A Novel Drug Delivery System (Higuchi, T et al, ACS Symposium Series, Vol. 14) and Bioreversible Carriers in Drug Design (Edward B. Roche, American Pharmaceutical Association and Pergamon Press, 1987), both of which are fully incorporated herein by reference. Exemplary advantages of prodrugs include, but are not limited to, their physical properties, such as enhanced water solubility at physiological pH for parenteral administration, or enhanced absorption in the digestive tract, or enhanced stability of the drug for long-term storage compared to the parent compound.

[0026] Prodrugs known in the art include acid derivatives, such as esters prepared by reacting the parent acid with a suitable alcohol, amides prepared by reacting the parent acid compound with an amine, and the basic groups of acylated base derivatives. Of course, other prodrug derivatives can be combined with other features disclosed in the present application to improve biopharmaceutical efficacy. Therefore, it will be appreciated by those skilled in the art that some compounds disclosed in the present application with free amino groups, hydroxyl groups or carboxyl groups can be converted into prodrugs. Prodrugs include compounds with amino acid residues, or compounds with polypeptide chains of two or more (e.g., two, three or four) amino acid residues, and the amino acid residues are covalently linked to the free amino groups, hydroxyl groups or carboxyl groups of the compounds disclosed in the present application through peptide bonds. Amino acid residues include 20 natural amino acids generally represented by three letter symbols, and also include 4-hydroxyproline, hydroxylysine, desmosine, isodesmosine, 3-methylhistidine, norvaline, β-alanine, γ-aminobutyric acid, citrulline, homocysteine, homoserine, ornithine and methionine sulfone. Prodrugs also include compounds having a carbonate, carbamate, amide, or alkyl ester moiety covalently bonded to any of the above substituents disclosed herein.

[0027] As used herein, the term "pharmaceutically acceptable excipient or carrier, diluent" refers to a pharmaceutically acceptable material, composition or carrier, such as a liquid or solid filler, diluent, excipient, solvent or encapsulating material, which is involved in delivering or transporting the agent from one organ or part of the body to another. Each carrier must be "acceptable", i.e., compatible with the other ingredients of the formulation and not harmful to the patient. Examples of materials that can be used as pharmaceutically acceptable carriers include: sugars, such as lactose, glucose and sucrose; starches, such as corn starch and potato starch; cellulose and its derivatives, such as sodium carboxymethylcellulose, ethylcellulose and cellulose acetate; powdered tragacanth; malt; gelatin; talc; excipients, such as cocoa butter and suppository waxes; oils, such as peanut oil, cottonseed oil, safflower oil, sesame oil, olive oil, corn oil and soybean oil; glycols, such as propylene glycol; polyols, such as glycerol, sorbitol, mannitol and polyethylene glycol; esters, such as ethyl oleate and ethyl laurate; agar; buffers, such as magnesium hydroxide and aluminum hydroxide; alginic acid; pyrogen-free water; isotonic saline; Ringer's solution; ethanol; phosphate buffered saline; and other nontoxic, compatible substances used in pharmaceutical formulations. Wetting agents, emulsifiers and lubricants, such as sodium lauryl sulfate, magnesium stearate and polyethylene oxide-polypropylene oxide copolymers, as well as coloring agents, release agents, coating agents, sweetening, flavoring and perfuming agents, preservatives and antioxidants can also be present in the compositions.

[0028] As used herein, the terms "isolated" or "purified" refer to material that is substantially or essentially free from components normally found in its native state. Purity and homogeneity are typically determined using analytical chemistry techniques, such as polyacrylamide gel electrophoresis or high performance liquid chromatography.

[0029] As used herein, the term "subject" refers to any animal (e.g., mammal), including but not limited to humans, non-human primates, rodents, etc., that is the recipient of a particular treatment. Generally, the terms "subject" and "patient" are used interchangeably herein to refer to a human subject.

[0030] As used herein, "low dose" means a dose that is at least 5% (e.g., at least 10%, 20%, 50%, 80%, 90%, or even 95%) lower than the lowest standard recommended dose for a particular compound formulated for a given route of administration for the treatment of any human disease or disorder. For example, a "low dose" of a drug formulated for administration by inhalation is different from a "low dose" of the same drug formulated for oral administration.

[0031] As used herein, "high dose" refers to a particular compound used for the treatment of any human disease or disorder that is at least 5% higher (e.g., at least 10%, 20%, 50%, 100%, 200%, or even 300%) than the highest standard recommended dose.

[0032] Isotopically labeled compounds are also within the scope of the present disclosure. As used herein, "isotopically labeled compounds" or "isotopic derivatives" refer to the presently disclosed compounds, including pharmaceutically acceptable salts and prodrugs thereof, each as described herein, in which one or more atoms are replaced by an atom having an atomic mass or mass number different from the atomic mass or mass number usually found in nature. Examples of isotopes that can be incorporated into the presently disclosed compounds include isotopes of hydrogen, carbon, nitrogen, oxygen, phosphorus, fluorine, and chlorine, for example, respectively. 2 H. 3 H. 13 C. 14 C. 15 N. 18 O. 17 O. 31 P. 32 P. 35 S. 18 F and 36 Cl.

[0033] By isotopically labeling the presently disclosed compounds, the compounds can be used in drug and / or substrate tissue distribution assays. Tritiated ( 3 H) and carbon-14 ( 14 C) labeled compounds because they are easy to prepare and detect. In addition, the use of heavier isotopes such as deuterium ( 2 H) substitution may bring certain therapeutic advantages that arise from greater metabolic stability, such as increased in vivo half-life or reduced dosage requirements, and may therefore be preferred in certain circumstances. The currently disclosed isotopically labeled compounds, including their pharmaceutically acceptable salts, esters, and prodrugs, may be prepared by any method known in the art. 13 C substitution is usually sufficient 12 C may also bring beneficial effects. (See, WO 2007 / 005643, WO 2007 / 005644, WO 2007 / 016361 and WO 2007 / 016431).

[0034] For example, deuterium ( 2 H) is combined with the compounds disclosed in the present application to control the oxidative metabolism of the compounds through the primary kinetic isotope effect. The primary kinetic isotope effect is a change in the rate of a chemical reaction caused by isotopic nuclear exchange, which in turn is caused by a change in the ground state energy required for covalent bond formation after this isotopic exchange. The exchange of heavier isotopes generally causes the ground state energy of the chemical bond to be reduced, resulting in a reduction in rate-limiting bond breakage. If bond breakage occurs in or near the saddle point region along the coordinates of a multi-product reaction, the product distribution ratio can be significantly changed. To explain, if deuterium is bonded to a non-replaceable position on a carbon atom, then k M / kD = 2-7. If this rate difference is successfully applied to the easily oxidizable compounds disclosed in the present application, the properties of the compounds in vivo can be significantly changed, thereby improving the pharmacokinetic properties.

[0035] When discovering and developing therapeutic agents, those skilled in the art can optimize pharmacokinetic parameters while maintaining the desired in vitro properties. It can be reasonably believed that many compounds with poor pharmacokinetic properties are prone to oxidative metabolism. Existing in vitro liver microsome assays provide valuable information about such oxidative metabolic processes, so that the deuterated compounds disclosed herein with improved stability can be rationally designed by anti-oxidative metabolism. Thus the pharmacokinetic properties of the compounds disclosed herein are significantly improved, and this improvement can be quantitatively represented by the extension of the half-life (t / 2) in vivo, the concentration (Cmax) of the maximum therapeutic effect, the area under the dose response curve (AUC), and F, and can also be represented by the clearance rate, dosage, and material cost reduced.

[0036] The following is intended to illustrate the above: compounds with multiple potential attack sites of oxidative metabolism, such as benzyl hydrogen atoms and hydrogen atoms bonded to nitrogen atoms, various combinations of hydrogen atoms are replaced by deuterium atoms in the analogs, so that part, most or all of the hydrogen atoms are replaced by deuterium atoms. Determining the half-life is conducive to accurately determining the degree of improvement in antioxidant metabolic capacity. In this way, the half-life of the parent compound can be extended by up to 100% due to this type of deuterium-hydrogen exchange.

[0037] Deuterium-hydrogen exchange in the compounds disclosed herein can also be used to achieve favorable modifications of the metabolite profile of the starting compound to reduce or eliminate undesirable toxic metabolites. For example, if toxic metabolites occur through oxidative carbon-hydrogen (CH) bond cleavage, it is reasonable to assume that deuterated compounds will greatly reduce or eliminate the generation of undesirable metabolites, even if the specific oxidation is not a rate-determining step. For more information on deuterium-hydrogen exchange in the prior art, see, for example, Hanzlik et al., J. Org. Chem. 55, 3992-3997, 1990, Reider et al., J. Org. Chem. 52, 3326-3334, 1987, Foster, Adv. Drug Res. 14, 1-40, 1985, Gillette et al, Biochemistry 33 (10) 2927-2937, 1994, and Jarman et al. Carcinogenesis 16 (4), 683-688, 1993.

[0038] After their preparation, the compounds of the invention are preferably isolated, purified to obtain compositions having a weight content equal to or greater than 95% ("substantially pure"), and then used or formulated as described herein. In some embodiments, the compounds of the invention are greater than 99% pure.

[0039] The combinations of substituents and variables contemplated by the present invention are intended only to those combinations that result in the formation of stable compounds. "Stable" herein refers to compounds with manufacturable stability that maintains the integrity of the compound for a sufficient period of time to be used for the purposes detailed herein (e.g., therapeutic or prophylactic administration to a subject).

[0040] In the definitions of variables herein, recitation of a listed chemical group includes definitions of that variable as a single group or a combination of the listed groups.Recitation of an embodiment of a variable herein includes that embodiment as a single embodiment or in combination with any other embodiment or moiety. DETAILED DESCRIPTION

[0041] The present invention provides a novel small molecule compound, a synthesis method thereof, a pharmaceutical composition and a method for using the same for treating or alleviating various diseases or disorders.

[0042] The main feature of the present invention is that the disclosed compounds are cancer targeting and sustained-release therapeutic agents, providing targeted sustained delivery. The conjugate of the present invention is composed of a tissue protein binder, a cleavable linker and a small molecule drug. After local injection of the conjugate, the tissue protein binder as a "molecular glue" binds to the tissue protein in the solid tumor, thereby retaining the conjugate in the solid tumor without leaking into the systemic circulation. Then, the small molecule drug is slowly released from the conjugate by the cleavage of the cleavable linker. Due to the slow but continuous release of the drug in the solid tumor, the tumor elimination effect is enhanced, and adverse reactions can be reduced at the same time, because the drug released into the systemic circulation is controlled to a minimum amount. The dosage regimen can be determined according to the half-life of the conjugate.

[0043] In one aspect, the present invention generally relates to a compound having structural formula (I): in, X is CHR or NR, R is H or alkyl, or a pharmaceutically acceptable form or isotopic derivative thereof.

[0044] In some embodiments, the compound of formula (I) is selected from:

[0045] In another aspect, the present invention generally relates to a compound having structural formula (II): or a pharmaceutically acceptable form or isotopic derivative thereof.

[0046] In some embodiments, the compound represented by formula (II) is selected from:

[0047] In another aspect, the present invention generally relates to a compound having the following structural formula: or a pharmaceutically acceptable form or isotopic derivative thereof.

[0048] In another aspect, the present invention generally relates to a compound having structural formula (III): wherein n is an integer selected from 2-8 (i.e., 2, 3, 4, 5, 6, 7 or 8), or a pharmaceutically acceptable form or isotopic derivative thereof.

[0049] In some embodiments, the compound represented by formula (III) is selected from:

[0050] In another aspect, the present invention generally relates to a compound having structural formula (IV): wherein n is an integer selected from 2-10 (e.g., 2, 3, 4, 5, 6, 7, 8, 9 or 10), or a pharmaceutically acceptable form or isotopic derivative thereof.

[0051] In some embodiments, the compound represented by formula (IV) is selected from:

[0052] In another aspect, the present invention generally relates to a compound having structural formula (V): in, Where R 2 is H or (=O)(R 3 )2,R 3 is an alkyl group, L is a single bond or a group selected from the following: k is an integer selected from 0-4 (eg, 0, 1, 2, 3 or 4), or a pharmaceutically acceptable form or isotopic derivative thereof.

[0053] In some embodiments, the compound represented by formula (V) is selected from:

[0054] In another aspect, the present invention generally relates to a compound having structural formula (VI): in, Where R 2 is H or (=O)(R 3 ), R 3 is an alkyl group, L is a single bond or a group selected from the following: k is an integer selected from 0-4 (e.g., 0, 1, 2, 3 or 4), or a pharmaceutically acceptable form or isotopic derivative thereof.

[0055] In some embodiments, the compound represented by formula (VI) has the following structure:

[0056] In another aspect, the present invention generally relates to a compound having the following structural formula: or a pharmaceutically acceptable form or isotopic derivative thereof.

[0057] In another aspect, the present invention generally relates to a compound having the following structural formula: or a pharmaceutically acceptable form or isotopic derivative thereof.

[0058] In another aspect, the present invention generally relates to a compound having the following structural formula: or a pharmaceutically acceptable form or isotopic derivative thereof.

[0059] In another aspect, the present invention generally relates to a compound having the following structural formula: or a pharmaceutically acceptable form or isotopic derivative thereof.

[0060] In another aspect, the present invention generally relates to a compound having the following structural formula: or a pharmaceutically acceptable form or isotopic derivative thereof.

[0061] In another aspect, the present invention generally relates to a compound having the following structural formula: or a pharmaceutically acceptable form or isotopic derivative thereof.

[0062] In another aspect, the present invention generally relates to a pharmaceutical composition comprising a compound disclosed in the present application and a pharmaceutically acceptable excipient or carrier, diluent.

[0063] In some embodiments, the pharmaceutical compositions of the present invention are effective in treating or alleviating cancer or related diseases or disorders.

[0064] In another aspect, the present invention generally relates to a unit dosage form comprising a pharmaceutical composition comprising a compound disclosed herein.

[0065] In another aspect, the present invention generally relates to a method for treating or alleviating a disease or disorder, comprising administering to a subject in need thereof a pharmaceutical composition comprising a compound disclosed herein and a pharmaceutically acceptable excipient or carrier, diluent.

[0066] In some embodiments, the disease or disorder is cancer or a disease or disorder related thereto.

[0067] In another aspect, the present invention generally relates to a use comprising using a compound disclosed herein to treat or alleviate a disease or disorder.

[0068] In another aspect, the present invention generally relates to a use for preparing a drug for treating or alleviating a disease or disorder, comprising using a compound disclosed in the present application and a pharmaceutically acceptable excipient or carrier, diluent.

[0069] The composition of the present invention can be administered orally, parenterally, by inhalation aerosol, topical, rectal, nasal, oral, vaginal or implantable drug box. The term "parenteral" herein includes subcutaneous, intravenous, intramuscular, intraarticular, intrasynovial, intrasternal, intrathecal, intrahepatic, intralesional and intracranial injection or infusion techniques. Preferably, the composition is administered orally, intraperitoneally or intravenously. The sterile injection form of the composition of the present invention includes aqueous or oily suspensions. According to technology known in the art, suitable dispersants or wetting agents and suspending agents are used to prepare these suspensions. Sterile injection preparations can also be sterile injection solutions or suspensions in nontoxic parenteral acceptable diluents or solvents, such as solutions in 1,3-butanediol. Acceptable carriers and solvents include water, Ringer's solution and isotonic sodium chloride solution. In addition, sterile fixed oils are generally used as solvents or suspension media.

[0070] Based on this, any mild fixed oil includes synthetic monoglycerides or diglycerides. Fatty acids, such as oleic acid and its glyceride derivatives, can be used to prepare injections. Natural drug acceptable oils, such as olive oil or castor oil, especially their polyoxyethylated forms can also be used. These oil solutions or suspensions also contain long-chain alcohol diluents or dispersants, such as carboxymethyl cellulose or similar dispersants. They are commonly used to prepare pharmaceutically acceptable dosage forms, including emulsions and suspensions. Other commonly used surfactants can also be used for preparation. For example, Tween, Span and other emulsifiers or biopharmaceutical enhancers, they are commonly used to prepare pharmaceutically acceptable solids, liquids or other dosage forms.

[0071] The pharmaceutically acceptable compositions of the present invention can be orally administered in any orally acceptable dosage form. Exemplary oral dosage forms are capsules, tablets, aqueous suspensions or solutions. For oral tablets, commonly used carriers include lactose and corn starch. Lubricants such as magnesium stearate are also usually included. For oral administration in capsule form, useful diluents include lactose and dried corn starch. When an aqueous suspension is used for oral administration, the active ingredient is mixed with an emulsifier and a suspending agent. Optionally, sweeteners, flavoring agents or coloring agents may also be added if desired.

[0072] Alternatively, the pharmaceutically acceptable compositions of the invention are administered rectally in the form of suppositories. These can be prepared by mixing the agent with a suitable non-irritating excipient that is solid at room temperature but liquid at rectal temperature so that it melts in the rectum to release the drug. Such materials include cocoa butter, beeswax, and polyethylene glycol.

[0073] The pharmaceutically acceptable compositions of the present invention may also be administered topically, particularly when the target of treatment includes areas or organs that are easily accessible by topical application, including diseases of the eyes, skin, or lower intestinal tract. Topicals suitable for these areas or organs can be readily prepared.

[0074] Topical application to the lower intestinal tract may be achieved in a rectal suppository formulation (see above) or in a suitable enema formulation. Topical skin patches may also be used.

[0075] For topical use, the pharmaceutically acceptable composition provided is formulated in a suitable ointment containing an active ingredient suspended or dissolved in one or more carriers. Exemplary carriers of topical compounds are mineral oil, liquid petrolatum, white petrolatum, propylene glycol, polyoxyethylene, polyoxypropylene compounds, emulsifying wax and water. Alternatively, the pharmaceutically acceptable composition provided can be formulated into a suitable milk or cream containing an active ingredient suspended or dissolved in one or more pharmaceutically acceptable carriers. Suitable carriers include, but are not limited to, mineral oil, sorbitan monostearate, polysorbate 60, cetyl ester wax, cetyl alcohol, 2-octyldodecanol, benzene MeOH and water.

[0076] Alternatively, the pharmaceutically acceptable compositions of the present invention can be administered by nasal aerosol spray or inhalation. Such compositions are prepared by techniques known in the art of pharmaceutical preparations and are prepared in the form of saline solutions, using benzene MeOH or other suitable preservatives, absorption enhancers for improving bioavailability, fluorocarbons and / or other conventional solubilizing agents or dispersants.

[0077] Most preferably, the pharmaceutically acceptable compositions of the present invention are formulated for oral administration. Such preparations can be administered with or without food. In certain embodiments, the pharmaceutically acceptable compositions of the present invention are administered without food. In certain embodiments, the pharmaceutically acceptable compositions of the present invention are administered with food.

[0078] The amount of the compound of the present invention, which is optionally combined with a carrier material to generate a single dosage composition, will vary depending on the host being treated, the specific mode of administration. Preferably, the provided compositions should be formulated to be administered to patients receiving these compositions at a compound dosage of 0.01-100 (mg / kg) / day.

[0079] It should also be understood that the specific dosage and treatment regimen for any particular patient depends on a variety of factors, including the activity of the specific compound used; the patient's age, weight, general health, sex, diet; administration time, excretion rate, drug combination, the diagnosis of the treating physician, and the severity of the specific disease being treated. The amount of the compound of the present invention in the composition also depends on the specific compound in the composition. Example

[0080] As described in the following examples, in some exemplary embodiments, compounds are prepared according to the following steps. It should be understood that although the overall synthetic methods of certain compounds of the present invention are described herein, the following methods and other methods known to those of ordinary skill in the art can also be applied to all compounds and any subclasses and species in these compounds, as described in this application.

[0081] The compound numbers used in the following examples correspond to the compound numbers listed above.

[0082] 1 H spectra were recorded using a Varian Mercury 400 spectrometer operating at 400 MHz. 13 C NMR was recorded at 100 MHz operation. Proton chemical shifts were referenced to the residual proton resonances in internal CDCl3 (7.26 ppm). Carbon chemical shifts were referenced to the deuterated solvent signal in internal CDCl3 (77.20 ppm).

[0083] LC-MS spectra were recorded on a Shimadzu LC-MS2020 using an Agilent C18 column (Eclipse XDB-C18, 5um, 2.1x 50mm) at a flow rate of 1 mL / min. Mobile phase A: 0.1% formic acid in water; mobile phase B: 0.1% formic acid in acetonitrile. A conventional gradient method was used. Time (min) A B 0 95 5 3 0 100 4 0 100 4.05 95 5

[0084] HPLC analysis was performed on an Agilent 1200 HPLC using a Zorbax Eclipse XDB C18 column (2.1 x 150 mm) at a flow rate of 1 mL / min. Mobile phase A: 0.1% TFA in water; Mobile phase B: 0.1% TFA in acetonitrile. Conventional methods were used with the following gradient. Time (min) Mobile phase A Mobile phase B 0 95 5 15 0 100 16 0 100 16.5 95 5 16.5 stop

[0085] Prep-HPLC was performed on a Varian ProStar using a Hamilton C18 PRP-1 column (15 x 250 mm) at a flow rate of 20 mL / min. Mobile phase A: 0.1% TFA aqueous solution; mobile phase B: 0.1% TFA acetonitrile solution. A conventional gradient method was used. Time (min) Mobile phase A Mobile phase B 0 90 10 30 30 70 35 10 100 40 90 10 45 stop Example 1 (R)-4,11-diethyl-4-methyl-3,14-dioxo-3,4,12,14-tetrahydro-1H-pyrano[3′,4′:6,7]indolizino[1,2-b]quinolin-9-yl 4-(4-iodophenyl)butyric acid methyl ester (1) Synthesis Scheme 1

[0086] Step 1: To a solution of compound 1-2 (600 mg, 2.06 mmol) in DMF (10 mL) was added EDCI (800 mg, 4.18 mmol) and HOBt (190 mg, 1.40 mmol). After stirring for 5 minutes, compound 1-1 (SN-38, 500 mg, 1.27 mmol) was added and the mixture was stirred at room temperature for 16 hours. After the reaction was completed, water (100 mL) was added and the mixture was stirred at room temperature for 30 minutes. A white precipitate was completely formed. The resulting mixture was filtered and washed with water to obtain an off-white solid. The crude product was then ground with acetonitrile for 1 hour and filtered. The resulting filter cake was then washed with acetonitrile and dried to obtain compound 1 (505 mg, yield: 59%) as an off-white solid. 1 H NMR (400MHz, DMSO-d6) δ8.19 (d, J = 9.1 Hz, 1H), 8.04-7.94 (m, 1H), 7.66 (td, J = 10. 1,9.2,4.6Hz,3H),7.32(s,1H),7.10(d,J=7.8Hz,2H),6.53(s,1H),5.44(s,2H), 5.32(s,2H),3.17(q,J=7.6Hz,2H),2.76-2.62(m,4H),1.98(p,J=7.4Hz,2H),1.8 7(hept,J=7.0Hz,2H),1.28(t,J=7.5Hz,3H),0.88(t,J=7.3Hz,3H).LCMS:m / z Calculate C 32 H 29 IN2O6: 664.50; yield: 665.2 [M+H] + . Example 2 (R)-4,11-diethyl-4-methyl-3,14-dioxo-3,4,12,14-tetrahydro-1H-pyrano[3',4':6,7]indolizino[1,2-b]quinolin-9-yl 2-methyl-4-(4-iodophenyl)butyric acid methyl ester (2) Synthesis Scheme 2

[0087] Step 1: At 0°C, in a nitrogen environment, LDA (2M, 2.5mL, 5mmol) was added dropwise to a stirred solution of compound 1-2 (500mg, 1.72mmol) in anhydrous THF (10mL). After addition, the mixture was stirred at 0°C for 30 minutes. MeI (538mg, 3.79mmol) was added dropwise and the reactant was stirred at room temperature for 16 hours. After the reaction was completed, the mixture was quenched with saturated NH4Cl (30mL) solution and extracted with EtOAc (30mL x 3). The organic layer was washed with brine, dried over anhydrous Na2SO4, filtered and concentrated. The crude product was purified by silica gel column (eluted with 30% EtOAc in petroleum ether) to obtain compound 2-1 (400mg, yield: 76%).

[0088] Step 2: At room temperature, a mixture of compound 2-1 (390 mg, 1.24 mmol) and compound 1-1 (194 mg, 0.496 mmol), HOBt (335 mg, 2.48 mmol), DMAP (30 mg, 0.248 mmol), EDCI (950 mg, 4.97 mmol) in DMF (5 mL) and DCM (5 mL) was stirred for 16 hours. After the reaction was complete, the mixture was distributed in EtOAc (100 mL) and water (100 mL). The organic layer was washed with salt water, dried over anhydrous Na2SO4, filtered and concentrated. The crude product was purified by silica gel column (eluted with a DCM solution of 5% MeOH) to obtain compound 2 (265 mg, yield: 30%). Example 3 (S)-4,11-Diethyl-4-hydroxy-3,14-dioxo-3,4,12,14-tetrahydro-1H-pyrano[3',4':6,7]indolizino[1,2-b]quinolin-9-yl(4-iodophenethyl)carbamate (3) Synthesis Scheme 3

[0089] Step 1: At 0 ℃, nitrogen environment, to the solution of compound 3-1 (1.0g, 4.11mmol) in anhydrous THF (10mL), a solution of borane-tetrahydrofuran complex (1M, in THF, 18.5mL) was added dropwise. The reaction mixture was stirred at 65 ℃ for 2 hours. After the reaction was completed, the mixture was cooled to 0 ℃ and 6N HCl (2mL) was added to quench. Then the obtained mixture was alkalized with 1N NaOH solution and extracted with DCM (50mL x 2). The combined organic layer was dried over anhydrous Na2SO4, filtered and concentrated to obtain compound 3-2 (1.0g, yield: 90%) as a colorless oil, which was directly used in the next step without further purification.

[0090] Step 2: Compound 3-3 (345 mg, 1.71 mmol) was dissolved in DCM (5 mL) and cooled to 0 ° C. A solution of compound 3-2 (210 mg, 0.85 mmol) and TEA (257 mg, 2.55 mmol) in DMSO (2 mL) was slowly added thereto. The mixture was stirred at 0 ° C for 1 hour. SN-38 (1-1, 330 mg, 0.84 mmol) and TEA (100 mg, 0.99 mmol) were added. The mixture was then stirred at room temperature for 3 hours. After the reaction was completed, the mixture was distributed in EtOAc (50 mL) and water (50 mL). The organic layer was washed with brine, dried over anhydrous Na2SO4, filtered and concentrated. The crude product was purified by silica gel column (eluted with 5% MeOH in DCM) to give compound 3 (120 mg, yield: 20%). Example 4 (S)-4,11-Diethyl-4-hydroxy-3,14-dioxo-3,4,12,14-tetrahydro-1H-pyrano[3',4':6,7]indolizino[1,2-b]quinolin-9-yl(4-iodophenethyl)(methyl)carbamate (4) Synthesis Scheme 4

[0091] Step 1: A mixture of compound 3-2 (1.0 g, 4.04 mmol) and Boc2O (1.7 g, 7.79 mmol), TEA (830 mg, 8.20 mmol) in DCM (10 mL) was stirred at room temperature for 2 hours. After the reaction was completed, the mixture was concentrated. The residue was purified by silica gel column (eluted with 10% EtOAc in petroleum ether) to give compound 4-1 (1.1 g, yield: 80%) as a white solid. LCMS: m / z calculated for C 13 H 18INO2: 347.20; Obtained: 348.21 [M+H] + .

[0092] Step 2: At 0°C, NaH (60%, 450mg, 11.25mmol in mineral oil) was added in several portions to a solution of compound 4-1 (1.3g, 3.74mmol) in anhydrous DMF (5mL). After stirring for 1 hour, MeI (1.6g, 11.27mmol) was added to the mixture at one time. The mixture was then stirred at room temperature for 16 hours. After the reaction was completed, the mixture was quenched by adding ice water and partitioned between EtOAc (100mL) and water (50mL). The organic layer was washed with brine, dried over anhydrous Na2SO4 and concentrated. The crude product was purified by silica gel column (eluted with 5% EtOAc in petroleum ether) to give compound 4-2 (1.02g, yield: 75%) as a white solid. LCMS: m / z calculated for C 14 H 20 INO2:361.22; Obtained:306.04[M- t Bu+H] + .

[0093] Step 3: At room temperature, a mixture of compound 4-2 (1.02 g, 2.82 mmol) in EtOAc (5 mL) and a solution of HCl in EtOAc (4N, 5 mL) were stirred for 1 hour. After the reaction was complete, a white precipitate was formed completely. The white precipitate was filtered and washed with EtOAc to obtain compound 4-3 (610 mg, yield: 82%), which was directly used in the next step without further purification.

[0094] Step 4: A suspension of SN-38 (1-1, 250 mg, 0.637 mmol) and DIPEA (170 mg, 1.31 mmol) and compound 4-4 (215 mg, 0.706 mmol) in anhydrous DMF (5 mL) was stirred under nitrogen for 1 hour at 0°C. The mixture was then treated with a solution of compound 4-3 (227 mg, 0.763 mmol) and DIPEA (200 mg, 1.55 mmol). After stirring for another 2 hours, the resulting mixture was diluted with EtOAc (50 mL) and washed with water. The organic layer was washed with brine, dried over anhydrous Na2SO4 and concentrated. The crude product was purified by silica gel column (eluted with 2% MeOH in DCM) to give 4 (170 mg, yield: 39%) as a light yellow solid. 1H NMR(400MHz,Chloroform-d)δ8.37-8.16(m,1H),7.84(d,J=2.8Hz,1H),7.69(dd,J=5.6,3.0Hz,3H),7.61-7.48(m, 1H),7.35-7.28(m,1H),7.16-6.97(m,2H),5.79(dd,J=16.3,2.8Hz,1H),5.49-5.26(m,3H),3.91(s,1H),3.80(t,J= 7.1 Hz, 1H), 3.66 (t, J = 7.8 Hz, 1H), 3.53 (d, J = 2.8 Hz, 1H), 3.19 (d, J = 7.4 Hz, 1H), 3.16 (d, J = 2.8 Hz, 1H), 3.09 (d, J = 2.8 Hz, 1H), 3.01-2.91 (m, 2H), 1.93 (ddd, J = 15.0, 7.4, 4.0 Hz, 2H), 1.48-1.38 (m, 3H), 1.13-1.02 (m, 3H). LCMS: m / z calculated for C 32 H 30 IN3O6: 679.51; obtained: 680.31 [M+H] + . Example 5 (S)-4,11-Diethyl-4-hydroxy-3,14-dioxo-3,4,12,14-tetrahydro-1H-pyrano[3',4':6,7]indolizino[1,2-b]quinolin-9-yl 2-(4-isobutylphenyl) propionate (5) Synthesis Scheme 5

[0095] Step 1: At room temperature, a mixture of compound 5-1 (236.6 mg, 1.15 mmol) and EDCI (438.1 mg, 2.29 mmol), HOBt (103.2 mg, 0.76 mmol) in DMF (3 mL) was stirred for 5 minutes. Compound 1-1 (300 mg, 0.76 mmol) was added and the mixture was stirred at room temperature for 15 hours. The mixture was distributed in EtOAc (30 mL) and water (30 mL). The organic layer was washed with brine, dried over anhydrous Na2SO4, filtered and concentrated. The crude product was purified by silica gel column (eluted with 2% MeOH in DCM solution) to obtain compound 5 (324 mg, yield: 72%) as a white solid. 1H NMR (500MHz, DMSO-d6) δ8.18(d,J=9.1Hz,1H),7.89(d,J=2.4Hz,1H),7.50(dd,J=9.2,2.5H z,1H),7.39-7.36(m,2H),7.32(s,1H),7.22-7.19(m,2H),6.53(s,1H),5.43(s,2H),5.31( s, 2H), 4.15 (q, J = 7.1 Hz, 1H), 3.15 (q, J = 7.6 Hz, 2H), 2.46 (d, J = 7.2 Hz, 2H), 1.92-1.81 (m, 3H), 1.57 (d, J = 7.1 Hz, 3H), 1.27 (t, J = 7.6 Hz, 3H), 0.88 (dd, J = 7.1, 2.3 Hz, 9H). LCMS: m / z calculated for C 35 H 36 N2O6: 580.68; Obtained: 581.47 [M+H] + . Example 6 (S)-4,11-Diethyl-4-hydroxy-3,14-dioxo-3,4,12,14-tetrahydro-1H-pyrano[3',4':6,7]indolizino[1,2-b]quinolin-9-yl(S)-2-(6-methoxynaphthalen-2-yl)propanoate (6) Synthesis Scheme 6

[0096] Step 1: A mixture of compound 6-1 (176.0 mg, 0.76 mmol) and SN-38 (1-1) (150 mg, 0.38 mmol), HOBt (51.6 mg, 0.38 mmol), EDCI (219.0 mg, 1.15 mmol) in DMF (3 mL) was stirred for 9 hours at room temperature. After the reaction was completed, the reaction mixture was diluted with EtOAc and washed with water. The organic layer was washed with brine, dried over anhydrous Na2SO4 and concentrated. The crude product was purified by column (eluted with 2% MeOH in dichloromethane) to give 6 (185 mg, yield: 80%) as a white solid. 1H NMR (400MHz, DMSO-d6) δ8.16(d,J=9.1Hz,1H),7.91(dd,J=4.4,2.1Hz,2H),7.87(d,J=8.7Hz,2H),7.58(dd ,J=8.5,1.8Hz,1H),7.52(dd,J=9.1,2.5Hz,1H),7.34(d,J=2.6Hz,1H),7.30(s,1H),7.19(dd,J=9.0,2.5Hz , 1H), 6.53 (s, 1H), 5.43 (s, 2H), 5.30 (s, 2H), 4.32 (q, J = 7.1 Hz, 1H), 3.87 (s, 3H), 3.14 (q, J = 7.5 Hz, 2H), 1.85 (dq, J = 14.2, 7.1 Hz, 2H), 1.66 (d, J = 7.1 Hz, 3H), 1.25 (t, J = 7.6 Hz, 3H), 0.87 (t, J = 7.3 Hz, 3H). LCMS: m / z calculated for C 36 H 32 N2O7: 604.66; Obtained: 605.36.[M+H] + .TLC(DCM:MeOH / 40:1):R f (Compound 6-1) = 0.5; R f (Compound 1-1) = 0.3; R f (6) = 0.37. Example 7 (S)-4,11-diethyl-4-hydroxy-3,14-dioxo-3,4,12,14-tetrahydro-1H-pyrano[3',4':6,7]indolizino[1,2-b]quinolin-9-yl(R)-2-(4-isobutylphenyl)propanoate (7) Synthesis Scheme 7

[0097] Step 1: At room temperature, a mixture of compound 7-1 (107 mg, 0.51 mmol), EDCI (198.2 mg, 1.04 mmol) and HOBt (46.7 mg, 0.35 mmol) in DMF (3 mL) was stirred for 5 minutes. Compound 1-1 (135.7 mg, 0.35 mmol) was added and the mixture was stirred at room temperature for 15 hours. The reaction mixture was distributed in EtOAc (20 mL) and water (20 mL). The organic layer was washed with brine, dried over anhydrous Na2SO4, filtered and concentrated. The crude product was purified by silica gel column (eluted with 2% MeOH in DCM solution) to obtain compound 7 (161 mg, yield: 80%) as a white solid.1 H NMR(500MHz,DMSO-d6)δ8.22-8.11(m,1H),7.93-7.86(m,1H),7.53-7.46(m,1H),7.38(d, J=7.6Hz,2H),7.32(d,J=2.3Hz,1H),7.21(d,J=7.8Hz,2H),6.53(s,1H),5.44(s,2H),5.33 (s, 2H), 4.16 (q, J = 7.2 Hz, 1H), 3.16 (p, J = 6.6, 6.1 Hz, 2H), 2.47 (d, J = 7.2 Hz, 2H), 1.93-1.80 (m, 3H), 1.57 (d, J = 7.1 Hz, 3H), 1.27 (t, J = 7.6 Hz, 3H), 0.88 (d, J = 6.3 Hz, 9H). LCMS: m / z calculated for C 35 H 36 N2O6: 580.68; Obtained: 581.47 [M+H] + . Example 8 (S)-4,11-Diethyl-4-hydroxy-3,14-dioxo-3,4,12,14-tetrahydro-1H-pyrano[3',4':6,7]indolizino[1,2-b]quinolin-9-yl(S)-2-(4-isobutylphenyl)propanoate (8) Synthesis Scheme 8

[0098] Step 1: At room temperature, a mixture of compound 8-1 (157.7 mg, 0.76 mmol), EDCI (292.0 mg, 1.53 mmol) and HOBt (68.8 mg, 0.51 mmol) in DMF (2 mL) was stirred for 5 minutes. Compound 1-1 (200 mg, 0.51 mmol) was added and the mixture was stirred at room temperature for 15 hours. The reaction mixture was distributed in EtOAc (30 mL) and water (30 mL). The organic layer was washed with brine, dried over anhydrous Na2SO4, filtered and concentrated. The crude product was purified by silica gel column (eluted with a DCM solution of 2% MeOH) to obtain compound 8 (197 mg, yield: 66%) as a white solid. 1H NMR (500MHz, DMSO-d6) δ8.17(d,J=9.1Hz,1H),7.89(t,J=2.3Hz,1H),7.50(dd,J=9.1,2.5H z,1H),7.39-7.36(m,2H),7.31(s,1H),7.22-7.19(m,2H),6.52(s,1H),5.43(s,2H),5.31( s, 2H), 4.15 (q, J = 7.1 Hz, 1H), 3.15 (q, J = 7.6 Hz, 2H), 2.46 (d, J = 7.1 Hz, 2H), 1.92-1.80 (m, 3H), 1.57 (d, J = 7.1 Hz, 3H), 1.26 (t, J = 7.6 Hz, 3H), 0.87 (dd, J = 7.0, 2.8 Hz, 9H). LCMS: m / z calculated for C 35 H 36 N2O6: 580.68; Obtained: 581.47 [M+H] + . Example 9 N-((S)-1-(((R)-1-(6-(2-(4-(4-iodophenyl)butyramido)ethyl)-4,8-dioxo-1,3,6,2- (2-(2-nitro-1-nitropropan-2-yl)-1-nitropropan-2-yl)pyrazine-2-carboxamide (9) Synthesis Scheme 9

[0099] Step 1: Add ethyl bromoacetate (9-2, 9.9 g, 59.2 mmol), KI (1.04 g, 6.26 mmol) and NaHCO3 (5.0 g, 59.5 mmol) to a solution of compound 9-1 (1.0 g, 6.24 mmol) in DMF (25 mL). Stir the mixture at room temperature for 14 hours. After the reaction is complete, the resulting mixture is diluted with EtOAc (200 mL), washed with water (200 mL x 2) and brine (200 mL). The organic layer is dried over anhydrous Na2SO4, filtered and concentrated. The residue is purified by silica gel chromatography (eluted with 20% EtOAc in petroleum ether) to obtain compound 9-3 (1.7 g, yield: 81%) as a colorless oil.

[0100] Step 2: A mixture of compound 9-3 (500 mg, 1.50 mmol) and TFA (1 mL) in DCM (4 mL) was stirred at room temperature for 1 hour. After the reaction was completed, the resulting mixture was concentrated to give compound 9-4 (600 mg) as a colorless oil, which was used directly in the next step without further purification.

[0101] Step 3: Compound 9-4 (600mg, crude product from step 2) is dissolved in DCM (5mL), and pH=8 is adjusted by adding EtN. Then the solution is added to the stirred mixture of compound 1-2 (360mg, 1.24mmol) and EDCI (431mg, 2.25mL) in DCM (10mL). After stirring for 16 hours, the obtained mixture is diluted with DCM (50mL), washed with water (50mL) and 1M HCl (50mLx 2). The organic layer is dried, filtered and concentrated through anhydrous NaSO to obtain colorless oily compound 9-5 (600mg), which is directly used in the next step without further purification.

[0102] Step 4: A mixture of compound 9-5 (600 mg, crude product from step 3) in MeOH (10 mL) was treated with aqueous NaOH (1 M, 3.67 mL, 3.67 mmol) and stirred at room temperature for 2 hours. After the reaction was completed, the mixture was concentrated to remove the organic solvent. The aqueous solution was washed with EtOAc (50 mL x 3) and acidified to pH = 2 with 1 M HCl to form a white precipitate. The precipitate was filtered and washed with water to give compound 9-6 (180 mg, yield after 3 steps: 26%) as a white solid. LCMS: m / z calculated for C 16 H 21 IN2O5:448.26; Obtained:449.03[M+H]+

[0103] Step 5: At 120 ° C, a mixture of compound 9-6 (180 mg, 0.40 mmol) and compound 9-7 (155 mg, 0.40 mmol) in toluene (18 mL) was stirred for 3 hours. After the reaction was completed, the mixture was concentrated. The residue was washed with MTBE and filtered to obtain a solid. The crude product was redissolved in acetonitrile and purified by pre-TLC (SiO2, DCM / acetonitrile=2 / 1) to obtain compound 9 (50.1 mg, yield: 15%) as a white solid. 1H NMR (400MHz, DMSO-d6) δ9.09 (s, 1H), 8.90 (d, J = 2.5Hz, 1H), 8.83 (d, J = 8.6Hz, 1H), 8.75 (s, 1H), 8.17 (s, 1H), 7.62 (d, J = 7.8Hz, 2H), 7.4 2(d,J=9.7Hz,1H),7.28(q,J=8.1,7.4Hz,4H),7.20(d,J=7.0Hz,1H),7.02(d,J=7.9Hz,2H),4.74(q,J=8.2Hz,1H),4.33(d,J=17.2Hz,1H ),4.24-4.11(m,2H),3.79(d,J=16.8Hz,1H),3.62-3.53(m,1H),3.22(s,1H),3.17(s,1H),3.06(d,J=8.5Hz,2H),2.51(s,1H),2.17-2.0 9(m,2H),1.80(t,J=7.7Hz,2H),1.59(s,1H),1.42(t,J=12.9Hz,1H),1.25(d,J=14.1Hz,4H),0.86(dd,J=13.0,6.5Hz,6H).LCMS: m / z calculation C 35 H 42 BIN6O7:796.47; Obtained:797.6[M+H]+ Example 10 N-((S)-1-(((R)-1-(6-(4-(4-(4-iodophenyl)butyramido)butyl)-4,8-dioxo-1,3,6,2- (10) Synthesis Scheme 10

[0104] Step 1: A solution of compound 1-2 (400 mg, 1.38 mmol), compound 10-1 (312 mg, 1.66 mmol), DMAP (17 mg, 0.14 mmol) and EDCI (397 mg, 2.07 mmol) in DCM (20 mL) was stirred at room temperature for 2 hours. After the reaction was completed, the mixture was diluted with DCM (100 mL) and washed with 1N HCl and brine. The organic layer was dried over anhydrous Na2SO4, filtered and concentrated to give compound 10-2 (500 mg), which was used directly in the next step without further purification.

[0105] Step 2: Compound 10-2 (500 mg, crude product from step 1) was dissolved in 4N HCl in EtOAc (5 mL) and the solution was stirred for 1 hour. After completion of the reaction, the mixture was concentrated to give compound 10-3 (450 mg), which was used directly in the next step without further purification.

[0106] Step 3: At room temperature, a mixture of compound 10-3 (450 mg, crude product from step 2), compound 10-4 (600 uL, 4.14 mmol) and triethylamine (1.0 mL, 6.90 mmol) in acetonitrile (10 mL) was stirred for 18 hours. After the reaction was completed, the reaction mixture was diluted with DCM (100 mL) and washed with water and brine. The organic layer was dried over Na2SO4, filtered and concentrated to give compound 10-5 (300 mg), which was used directly in the next step without further purification.

[0107] Step 4: Compound 10-5 (300 mg, crude product from step 3) was dissolved in 4N HCl in EtOAc (5 mL) and stirred for 2 hours. After the reaction was completed, the mixture was concentrated. The crude product was purified by prep-HPLC (preparative liquid chromatography) (C18 column, eluted with acetonitrile and H2O, TFA conditions) to obtain compound 10-6 (110 mg, yield after 4 steps: 13.4%), which was a light yellow oil.

[0108] Step 5: At 120 ° C, a mixture of compound 10-6 (112 mg, 0.235 mmol) and compound 9-7 (90 mg, 0.234 mmol) in toluene (5 mL) was stirred for 3 hours. After the reaction was completed, the mixture was concentrated. The residue was washed with MTBE and filtered to obtain a solid. The crude product was redissolved in acetonitrile and purified by pre-TLC (preparative thin layer chromatography) (SiO2, DCM / acetonitrile=3 / 1) to obtain compound 10 (51 mg, yield: 26%) as a white solid. 1H NMR (400MHz, DMSO-d6) δ9.07(s,1H),8.89(d,J=8.3Hz,1H),8.86(d,J=2.3Hz,1H),8.73(s,1H),7.88-7.79(m,1H),7.59(dd,J=8.2 ,1.9Hz,2H),7.34(d,J=9.6Hz,1H),7.30-7.20(m,4H),7.19-7.12(m,1H),7.03-6.95(m,2H),4.67(q,J=7.7Hz,1H),4.17(d,J=17. 3Hz,1H),4.05(d,J=17.4Hz,1H),3.95(d,J=16.6Hz,1H),3.63-3.45(m,2H),3.07(d,J=7.3Hz,6H),2.09-2.03(m,2H),1.77(p,J=7 .4Hz, 2H), 1.56 (s, 3H), 1.41 (t, J = 12.6Hz, 3H), 1.21 (d, J = 17.2Hz, 2H), 0.85 (d, J = 6.6Hz, 3H), 0.80 (d, J = 6.3Hz, 3H). LCMS: m / z calculation C 37 H 46 BIN6O7: 824.52; Obtained: 825.9.[M+H] + Embodiment 11 N-((S)-1-(((R)-1-(6-(3-(4-(4-iodophenyl)butyramido)propyl)-4,8-dioxo-1,3,6,2-dioxazaborolan-2-yl)-3-methylbutyl)amino)-1-oxo-3-phenylpropan-2-yl)pyrazine-2-carboxamide (11) Synthesis Scheme 11

[0109] Step 1: At room temperature, a mixture of compound 11-1 (1.0 g, 6.79 mmol), NaHCO3 (4.8 g, 57.07 mmol), KI (950 mg, 5.72 mmol) and compound 9-2 (9.5 g, 56.89 mmol) in DMF (20 mL) was stirred for 16 hours. After the reaction was completed, the mixture was distributed in EtOAc (100 mL) and water (100 mL). The organic layer was washed with brine (100 mL), dried over anhydrous Na2SO4 and concentrated. The crude product was purified by silica gel column (eluted with 15% EtOAc in petroleum ether) to obtain compound 11-2 (1.7 g, yield: 85%) as a colorless oil. TLC (DCM: MeOH / 10: 1): R f (Compound 11-1) = 0.2; TLC (petroleum ether: EtOAc / 2:1): R f (Compound 11-2) = 0.45.

[0110] Step 2: A solution of compound 11-2 (700 mg, 2.02 mmol) and TFA (4 mL) in DCM (4 mL) was stirred at room temperature for 1 hour. After the reaction was completed, the mixture was concentrated to give compound 11-3 (680 mg, yield: 70%) as a colorless oil, which was used directly in the next step without further purification. TLC (petroleum ether: EtOAc / 2:1): R f (Compound 11-2) = 0.45; TLC (DCM: MeOH / 5:1): R f (Compound 11-3) = 0.15.

[0111] Step 3: At room temperature, a mixture of crude compound 11-3 (680 mg, 1.43 mmol), compound 1-1 (527 mg, 1.82 mmol), EDCI (580 mg, 3.04 mmol) and DMAP (25 mg, 0.205 mmol) in DCM (10 mL) was stirred for 16 hours. After the reaction was completed, the mixture was partitioned between EtOAc (50 mL) and water (20 mL). The organic layer was washed with 1N HCl (50 mL x 2), saturated Na2CO3 solution and brine (50 mL), dried over anhydrous Na2CO3 and concentrated to give compound 11-4 (580 mg, yield: 78%) as a colorless oil, which was used directly in the next step without further purification. LCMS: m / z calculated for C 21 H 31 IN2O5: 518.39; Obtained: 519.09 [M+H] + .

[0112] Step 4: A mixture of compound 11-4 (580 mg, 1.12 mmol) and NaOH (290 mg, 7.25 mmol) in ethanol (10 mL) and H2O (5 mL) was stirred at room temperature for 4 hours. After the reaction was completed, the mixture was concentrated to remove the organic solvent. The remaining aqueous solution was adjusted to pH = 2 and purified by reverse phase flash chromatography (C18 column, eluted with acetonitrile and water, TFA conditions) to obtain compound 11-5 (220 mg, yield: 43%) as a white solid. LCMS: m / z calculated C 17 H 23 IN2O5: 462.28; Obtained: 463.51 [M+H] + .

[0113] Step 5: At 120°C, a mixture of compound 11-5 (120 mg, 0.259 mmol) and compound 9-7 (83 mg, 0.216 mmol) in toluene (5 mL) was stirred for 13 hours. After the reaction was completed, the mixture was concentrated. The residue was purified by pre-TLC (DCM: acetonitrile = 3: 1) to give 11 (63 mg, yield: 35%) as a white solid. 1 H NMR(400MHz,DMSO-d6)δ9.07(s,1H),8.92-8.83(m,2H),8.77-8.70(m,1H),7.74(s,1H),7.63-7.54(m,2H),7.38(d ,J=9.8Hz,1H),7.27(dd,J=13.3,7.8Hz,4H),7.19-7.14(m,1H),6.98(d,J=7.7Hz,2H),4.67(d,J=8.4Hz,1H),4.17- 4.05(m,2H),3.98(d,J=16.6Hz,1H),3.53(d,J=22.0Hz,2H),3.07(d,J=11.9Hz,6H),2.08(d,J=6.9Hz,2H),1.80-1 .70(m,3H),1.57(s,2H),1.42(t,J=13.1Hz,2H),1.21(d,J=18.3Hz,2H),0.82(dd,J=22.8,6.3Hz,6H).LCMS:m / z Calculate C 36 H 44 BIN6O7:810.50; Obtained:811.63[M+H] + . Example 12 N-((S)-1-(((R)-1-(6-(5-(4-(4-iodophenyl)butyramido)pentyl)-4,8-dioxo-1,3,6,2-dioxazaborolan-2-yl)-3-methylbutyl)amino)-1-oxo-3-phenylpropan-2-yl)pyrazine-2-carboxamide (12) Synthesis Scheme 12

[0114] Step 1: At room temperature, a mixture of compound 12-1 (500mg, 2.47mmol), NaHCO3 (2.1g, 24.9mmol), KI (410mg, 2.47mmol) and compound 9-2 (4.1g, 24.5mmol) in DMF (10mL) was stirred for 16 hours. After the reaction was completed, the mixture was distributed in EtOAc (50mL) and water (50mL). The organic layer was washed with brine (50mL), dried over anhydrous Na2SO4 and concentrated. The crude product was purified by silica gel column (eluted with 15% EtOAc petroleum ether solution) to obtain compound 12-2 (700mg, yield: 75%) as a colorless oil. TLC (DCM: MeOH / 10: 1): R f (Compound 12-1) = 0.2; TLC (petroleum ether: EtOAc / 2:1): R f (Compound 12-2) = 0.55.

[0115] Step 2: A solution of compound 12-2 (700 mg, 1.87 mmol) and TFA (4 mL) in DCM (4 mL) was stirred at room temperature for 1 hour. After the reaction was completed, the mixture was concentrated to give compound 12-3 (760 mg, yield: 80%) as a colorless oil, which was used directly in the next step without further purification. TLC (petroleum ether: EtOAc / 2:1): R f (Compound 12-2) = 0.55; TLC (DCM: MeOH / 5:1): R f (Compound 12-3) = 0.18.

[0116] Step 3: At room temperature, a mixture of crude compound 12-3 (660 mg, 1.51 mmol), compound 1-2 (488 mg, 1.68 mmol), EDCI (540 mg, 2.82 mmol) and DMAP (23 mg, 0.189 mmol) in DCM (10 mL) was stirred for 16 hours. After the reaction was completed, the mixture was distributed in EtOAc (50 mL) and water (20 mL). The organic layer was washed with 1N HCl (50 mL x 2), saturated Na2CO3 solution and brine (50 mL), dried over anhydrous Na2SO4 and concentrated to give a colorless oily compound 12-4 (700 mg, yield: 84%), which was directly used in the next step without further purification. TLC (petroleum ether: EtOAc / 2:1): R f (Compound 12-3) = 0.5; R f (Compound 12-4) = 0.2.

[0117] Step 4: A mixture of compound 12-4 (700 mg, 1.28 mmol) and NaOH (270 mg, 6.75 mmol) in ethanol (10 mL) and H2O (5 mL) was stirred at room temperature for 4 hours. After the reaction was completed, the mixture was concentrated to remove the organic solvent. The remaining aqueous solution was adjusted to pH = 2 and directly purified by reverse phase flash chromatography (C18 column, eluted with acetonitrile and water, TFA conditions) to obtain compound 12-5 (270 mg, yield: 43%) as a white solid. LCMS: m / z calculated C 19 H 27 IN2O5: 490.34; Obtained: 491.30 [M+H] + .

[0118] Step 5: At 120° C., a mixture of compound 12-5 (153 mg, 0.312 mmol) and compound 9-7 (100 mg, 0.260 mmol) in toluene (5 mL) was stirred for 13 hours. After the reaction was completed, the mixture was concentrated. The residue was purified by pre-TLC (DCM: acetonitrile = 3: 1) to give 12 (67 mg, yield: 25%) as a white solid. 1H NMR (400MHz, DMSO-d6) δ9.05(d,J=3.0Hz,1H),8.94-8.82(m,2H),8.71(d,J=3.3Hz,1H),7.81(s,1H),7.56(dd,J=8.1,2.8Hz ,2H),7.35(d,J=10.1Hz,2H),7.30-7.21(m,4H),7.19-7.13(m,1H),6.96(dd,J=8.4,2.8Hz,2H),4.66(s,1H),4.15(dd,J=17. 5,3.0Hz,1H),4.07-3.99(m,1H),3.93(dd,J=16.8,3.0Hz,1H),3.05(d,J=8.4Hz,6H),2.03(d,J=8.1Hz,2H),1.75(d,J=8.0Hz ,2H),1.54(s,4H),1.41(d,J=9.9Hz,3H),1.15(s,4H),0.83(dd,J=6.6,3.1Hz,3H),0.79(dd,J=6.6,3.1Hz,3H).LCMS: m / z calculation C 38 H 48 BIN6O7:838.55; Obtained:839.50[M+H] + . Embodiment 13 N-((2S)-1-(((1R)-1-(6-(4-(2-(4-isobutylphenyl)propionamido)butyl)-4,8-dioxo-1,3,6,2-dioxazaborolan-2-yl)-3-methylbutyl)amino)-1-oxo-3-phenylpropan-2-yl)pyrazine-2-carboxamide (13) Synthesis Scheme 13

[0119] Step 1: At room temperature, a mixture of compound 10-1 (2 g, 10.62 mmol), compound 9-2 (17.7 g, 106.23 mmol), NaHCO3 (8.92 g, 106.23 mmol) and KI (1.76 g, 10.62 mmol) in DMF (20 mL) was stirred for 16 hours. The reaction mixture was diluted with EtOAc (100 mL) and washed with water (100 mL). The organic layer was washed with brine, dried over anhydrous Na2SO4, filtered and concentrated. The crude product was purified by silica gel column (eluted with 30% EtOAc in petroleum ether) to obtain compound 13-1 (3.5 g, yield: 91%) as a yellow oil.

[0120] Step 2: To a solution of compound 13-1 (2 g, 5.55 mmol) in DCM (16 mL) was added TFA (4 mL) at room temperature, and the mixture was stirred for 1 hour. After the reaction was completed, the mixture was concentrated to give crude compound 13-2 (3 g), which was used directly in the next step.

[0121] Step 3: A mixture of compound 5-1 (1.14 g, 5.53 mmol), HATU (3.15 g, 8.29 mmol) and DIPEA (1.37 mL, 8.29 mmol) in DMF (2 mL) was stirred at room temperature for 10 minutes. Compound 13-2 (3 g, crude product from step 2) was added and the mixture was stirred for 3 hours. After the reaction was completed, the mixture was diluted with EtOAc (50 mL) and washed with water (50 mL). The organic layer was washed with brine, dried over anhydrous Na2SO4, filtered and concentrated. The crude product was purified by reverse phase flash chromatography (C18 column, eluted with acetonitrile and H2O, HCl conditions) to give compound 13-3 (1.8 g, yield after 2 steps: 72%). LCMS: m / z calculated for C 25 H 40 N2O5: 448.29; Obtained: 473.32 [M+H] + .

[0122] Step 4: To a mixture of compound 13-3 (1.8 g, 4.01 mmol) in ethanol (8 mL) and H2O (4 mL) was added LiOH (336.7 mg, 20.06 mmol). The mixture was stirred at room temperature for 1 hour. After the reaction was completed, the mixture was adjusted to pH = 3 with 1N HCl and concentrated. The crude product was purified by reverse phase flash chromatography (C18 column, eluted with acetonitrile and H2O, HCl conditions) to give compound 13-4 (1.1 g, yield: 70%). LCMS: m / z calculated C 21 H 32 N2O5: 392.50; yield: 393.33 [M+H] + .

[0123] Step 5: At 120 ° C, a mixture of compound 13-4 (1 g, 0.36 mmol) and compound 9-7 (115 mg, 0.30 mmol) in toluene (15 mL) was stirred for 17 hours. After the reaction was completed, the mixture was concentrated. The crude product was purified by silica gel column (eluted with 30% acetonitrile in DCM) to obtain compound 13 (1 g, yield: 53%) as a light yellow solid. 1H NMR (500MHz, DMSO-d6) δ9.09(dd,J=3.8,1.5Hz,1H),8.92-8.85(m,2H),8.73(ddd,J=5.1,2.5,1.5Hz,1H),7.97(td,J=5.8,2.1Hz,1H),7.35(dd,J=9 .9,6.0Hz,1H),7.31-7.15(m,7H),7.06(d,J=7.9Hz,2H),4.73-4.63(m,1H ),4.12(dd,J=17.4,3.6Hz,1H),4.03(dd,J=17.3,1.7Hz,1H),3.98-3.89(m ,1H),3.56(qd,J=8.1,7.0,3.5Hz,2H),3.48(dd,J=16.7,8.7Hz,1H),3.15 -2.97(m,6H),2.38(d,J=7.2Hz,2H),1.78(dp,J=13.5,6.7Hz,1H),1.62-1 .50(m,2H),1.50-1.40(m,2H),1.40-1.33(m,2H),1.32(dd,J=7.0,1.4Hz, 3H),1.21(ddt,J=13.7,10.2,4.5Hz,1H),0.92-0.74(m,12H).LCMS:m / z Calculate C 40 H 53 BN6O7: 740.41; Obtained: 742.01 [M+H] + . Embodiment 14 N-((S)-1-(((R)-1-(6-(4-((S)-2-(6-methoxynaphthalen-2-yl)propionamido)butyl)-4,8-dioxo-1,3,6,2-dioxazaborolan-2-yl)-3-methylbutyl)amino)-1-oxo-3-phenylpropan-2-yl)pyrazine-2-carboxamide (14) Synthesis Scheme 14

[0124] Step 1: At room temperature, a mixture of compound 6-1 (254 mg, 1.11 mmol), DIPEA (445 mg, 3.45 mmol), compound 13-2 (415 mg, crude product, about 70% purity, 1.12 mmol) and HATU (787 mg, 2.07 mmol) in DMF (3 mL) was stirred for 3 hours. After the reaction was completed, the mixture was partitioned between EtOAc (50 mL) and water (50 mL). The organic layer was washed with brine, dried over anhydrous Na2SO4 and concentrated. The crude product was purified by reverse phase flash chromatography (C18 column, eluted with acetonitrile and water, HCl conditions). The desired component was lyophilized to give compound 14-1 (380 mg, yield: 58%). LCMS: m / z calculated C 26 H 36 N2O6: 472.3; obtained: 473.32 [M+H] + .

[0125] Step 2: A mixture of compound 14-1 (380 mg, 0.80 mmol) and NaOH (160 mg, 4.01 mmol) in ethanol (5 mL) and H2O (5 mL) was stirred at room temperature for 3 hours. After the reaction was completed, the mixture was adjusted to pH = 7 with 1N HCl. The resulting mixture was concentrated and purified by reverse phase flash chromatography (C18 column, eluted with acetonitrile and water, HCl conditions). The desired fraction was lyophilized to give compound 14-2 (150 mg, yield: 45%). LCMS: m / z calculated C 26 H 36 N2O6:416.19; Obtained:417.13.[M+H] +

[0126] Step 3: At 120°C, a mixture of compound 14-2 (150 mg, 0.36 mmol) and compound 9-7 (115 mg, 0.30 mmol) in toluene (3 mL) was stirred for 17 hours. After the reaction was completed, the mixture was concentrated to remove the organic solvent. The crude product was purified by pre-HPLC (C18 column, eluted with acetonitrile and H2O, neutral conditions) to obtain compound 14 (30 mg, yield: 13%). 1H NMR (400MHz, DMSO-d6) δ9.05(d,J=4.0Hz,1H),8.86(d,J=13.7Hz,2H),8.68(s,1H),8.05(d,J=6.4Hz,1H),7.72(dt,J =13.6,6.0Hz,3H),7.47-7.40(m,1H),7.34(d,J=9.1Hz,1H),7.28-7.19(m,5H),7.18-7.08(m,2H),4.66(s,1H),4.09 (d,J=17.7Hz,1H),3.98(d,J=17.5Hz,1H),3.88(d,J=14.9Hz,1H),3.83(d,J=4.3Hz,3H),3.71(s,2H),3.06(s,6H),1 .53(s,2H),1.39(q,J=13.4,9.6Hz,6H),1.28-1.12(m,4H),0.83(t,J=5.2Hz,3H),0.79(t,J=5.5Hz,3H).LCMS: m / z calculation C 41 H 49 BN6O8:764.37; Obtained:765.43.[M+H] + . Embodiment 15 N-((S)-1-(((R)-1-(6-(4-((R)-2-(4-isobutylphenyl)propionamido)butyl)-4,8-dioxo-1,3,6,2-dioxazaborolan-2-yl)-3-methylbutyl)amino)-1-oxo-3-phenylpropan-2-yl)pyrazine-2-carboxamide (15) Synthesis Scheme 15

[0127] Step 1: At room temperature, a mixture of compound 7-1 (143 mg, 0.69 mmol), HATU (396 mg, 1.04 mmol) and DIPEA (224 mg, 1.73 mmol) in DMF (2 mL) was stirred for 10 minutes, and compound 13-2 (300 mg, crude product, about 70% purity, 0.81 mmol) was added. After stirring at room temperature for 3 hours, the mixture was diluted with EtOAc (20 mL) and washed with water (20 mL). The organic layer was washed with brine, dried over anhydrous Na2SO4, filtered and concentrated. The crude product was purified by reverse phase flash chromatography (C18 column, eluted with acetonitrile and H2O, HCl conditions) to give compound 15-1 (307 mg, yield: 99%). LCMS: m / z calculated for C 25 H40 N2O5: 448.60; Obtained: 449.62 [M+H] + .

[0128] Step 2: To a mixture of compound 15-1 (337 mg, 0.75 mmol) in ethanol (2 mL) and H2O (2 mL) was added LiOH.H2O (157.6 mg, 3.76 mmol). The mixture was then stirred at room temperature for 1 hour. After the reaction was completed, the mixture was adjusted to pH = 7 with 1N HCl and concentrated. The crude product was purified by reverse phase flash chromatography (C18 column, eluted with acetonitrile and H2O, HCl conditions) to give compound 15-2 (231 mg, yield: 78%). LCMS: m / z calculated for C 25 H 40 N2O5: 392.23; Obtained: 393.33 [M+H] + .

[0129] Step 3: At 120° C., a mixture of compound 15-2 (100 mg, 0.25 mmol) and compound 9-7 (81.6 mg, 0.21 mmol) in toluene (5 mL) was stirred for 17 hours. After the reaction was completed, the mixture was concentrated. The crude product was purified by pre-TLC (SiO2, acetonitrile / DCM=1 / 3) to obtain compound 15 (97 mg, yield: 61%) as a white solid. 1HNMR(500MHz,DMSO-d6)δ9.09(d,J=1.5Hz,1H),8.92-8.86(m,2H),8.74(dd ,J=2.5,1.5Hz,1H),7.97(t,J=5.8Hz,1H),7.34(d,J=9.8Hz,1H),7.31-7.27 (m,2H),7.27-7.23(m,2H),7.22-7.19(m,2H),7.19-7.15(m,1H),7.08-7.03 (m,2H),4.68(q,J=7.7Hz,1H),4.11(d,J=17.4Hz,1H),4.03(d,J=17.3Hz,1H ),3.92(d,J=16.7Hz,1H),3.56(qd,J=6.9,3.1Hz,2H),3.49(d,J=16.8Hz,1H ),3.13-2.98(m,6H),2.38(d,J=7.1Hz,2H),1.78(hept,J=6.8Hz,1H),1.57( ddt,J=13.7,6.7,3.6Hz,2H),1.49-1.34(m,4H),1.32(d,J=7.1Hz,3H),1.20 (ddd,J=17.2,10.2,5.0Hz,1H),0.83(dt,J=13.6,6.9Hz,12H).LCMS: m / z calculation C 40 H 53 BN6O7: 740.41; Obtained: 741.94 [M+H] + . Example 16 N-((S)-1-(((R)-1-(6-(4-((S)-2-(4-isobutylphenyl)propionamido)butyl)-4,8-dioxo-1,3,6,2-dioxazaborolan-2-yl)-3-methylbutyl)amino)-1-oxo-3-phenylpropan-2-yl)pyrazine-2-carboxamide (16) Synthesis Scheme 16

[0130] Step 1: At room temperature, a mixture of compound 8-1 (334 mg, 1.62 mmol), HATU (924 mg, 2.42 mmol) and DIPEA (716.8 μL, 4.04 mmol) in DMF (5 mL) was stirred for 10 minutes, and compound 13-2 (800 mg, crude product, 70% purity, 2.15 mmol) was added. After stirring at room temperature for 3 hours, the mixture was diluted with EtOAc (50 mL) and washed with water (50 mL). The organic layer was washed with brine, dried over anhydrous Na2SO4, filtered and concentrated. The crude product was purified by reverse phase flash chromatography (C18 column, eluted with acetonitrile and H2O, HCl conditions) to give compound 16-1 (706 mg, yield: 97%). LCMS: m / z calculated for C 25 H 40 N2O5: 448.60; Obtained: 449.62 [M+H] + .

[0131] Step 2: To a mixture of compound 16-1 (806 mg, 1.80 mmol) in ethanol (5 mL) and H2O (5 mL) was added LiOH.H2O (376.9 mg, 8.98 mmol), and the mixture was stirred at room temperature for 1 hour. After the reaction was completed, the mixture was adjusted to pH = 7 with 1N HCl and concentrated. The crude product was purified by reverse phase flash chromatography (C18 column, eluted with acetonitrile and H2O, HCl conditions) to give compound 16-2 (549 mg, yield: 78%). LCMS: m / z calculated C 25 H 40 N2O5: 392.23; Obtained: 393.33 [M+H] + .

[0132] Step 3: At 120° C., a mixture of compound 16-2 (100 mg, 0.25 mmol) and compound 9-7 (81.6 mg, 0.21 mmol) in toluene (5 mL) was stirred for 17 hours. After the reaction was completed, the mixture was concentrated. The crude product was purified by pre-TLC (acetonitrile / DCM=1 / 3) to obtain compound 16 (98 mg, yield: 62%) as a white solid. 1H NMR (500MHz, DMSO-d6) δ9.09(d,J=1.5Hz,1H),8.90-8.85(m,2H),8.74-8.71(m,1H),7.97(t,J=5.8Hz,1H),7.36(d,J=9.8Hz,1H),7.31-7.27(m ,2H),7.27-7.23(m,2H),7.23-7.20(m,2H),7.19-7.15(m,1H),7.08-7. 04(m,2H),4.75-4.64(m,1H),4.12(d,J=17.4Hz,1H),4.03(d,J=17.3Hz, 1H),3.92(d,J=16.7Hz,1H),3.61-3.52(m,2H),3.47(d,J=16.7Hz,1H), 3.14-2.98(m,6H),2.38(d,J=7.1Hz,2H),1.79(dh,J=13.6,6.8Hz,1H),1 .62-1.50(m,2H),1.50-1.34(m,4H),1.32(d,J=7.0Hz,3H),1.21(ddd,J=17.2,9.5,4.3Hz,1H),0.84(td,J=10.4,9.7,6.5Hz,12H).LCMS:m / z Calculate C 40 H 53 BN6O7: 740.41; obtained: 741.73 [M+H] + . Embodiment 17 N-((S)-1-(((R)-1-(6-(5-((S)-2-(4-isobutylphenyl)propionamido)pentyl)-4,8-dioxo-1,3,6,2-dioxazaborolan-2-yl)-3-methylbutyl)amino)-1-oxo-3-phenylpropan-2-yl)pyrazine-2-carboxamide (17) Synthesis Scheme 17

[0133] Step 1: NaHCO3 (4.15 g, 49.39 mmol), KI (820 mg, 4.93 mmol) and compound 9-2 (4.13 g, 24.73 mmol) were added to a solution of compound 17-1 (1.0 g, 4.94 mmol) in DMF (10 mL). The mixture was stirred at room temperature for 16 hours. After the reaction was completed, the mixture was distributed in EtOAc (100 mL) and water (100 mL). The organic layer was washed with brine, dried over anhydrous Na2SO4 and concentrated. The residue was purified by silica gel column (eluted with 30% EtOAc in petroleum ether) to obtain compound 17-2 (1.66 g, yield: 89%).

[0134] Step 2: A mixture of compound 17-2 (1 g, 2.67 mmol) in 4N HCl (EtOAc solution, 10 mL) and MeOH (0.5 mL) was stirred at room temperature for 2 hours. After the reaction was completed, the mixture was concentrated to give compound 17-3 (1 g, crude product), which was used directly in the next step without further purification.

[0135] Step 3: At room temperature, a solution of compound 17-3 (200 mg, 0.673 mmol), compound 8-1 (660 mg, 3.20 mmol), DIPEA (862 mg, 6.68 mmol) and HATU (1.52 g, 3.99 mmol) in DMF (5 mL) was stirred for 3 hours. After the reaction was completed, the mixture was diluted with EtOAc (50 mL) and washed with water (50 mL x 2) and brine (50 mL). The organic layer was dried over anhydrous Na2SO4, filtered and concentrated. The crude product was purified by silica gel column (eluted with 30% EtOAc in petroleum ether) to give compound 17-4 (623 mg, yield after 2 steps: 50%). LCMS: m / z calculated C 26 H 42 N2O5: 462.63; Obtained: 463.95 [M+H] + .

[0136] Step 4: At 0°C, NaOH (214 mg, 5.36 mmol) was added to a solution of compound 17-4 (620 mg, 1.34 mmol) in EtOH (6 mL) and H2O (3 mL), and the reaction was stirred at room temperature for 1 hour. The mixture was concentrated and adjusted to pH = 2 with 1N HCl at 0°C. The aqueous mixture was purified by reverse phase flash chromatography (C18 column, eluted with 55% acetonitrile aqueous solution, HCl conditions). The desired fraction was lyophilized to give compound 17-5 (209 mg, yield: 35%) as a white solid. LCMS: m / z calculated for C 22 H 34N2O5:406.52; Obtained:407.83[M+H] + .

[0137] Step 5: A mixture of compound 17-5 (172 mg, 0.388 mmol) and compound 9-7 (149 mg, 0.388 mmol) in toluene (3 mL) was stirred at 120° C. for 17 hours. After the reaction was completed, the mixture was concentrated. The crude product was purified by pre-TLC (acetonitrile: dichloromethane = 1:3) to give 17 (55 mg, yield: 18%) as a white solid. LCMS: m / z calculated for C 41 H 55 BN6O7: 754.74; Obtained: 755.93 [M+H] + . Embodiment 18 N-((S)-1-(((R)-1-(6-(6-((S)-2-(4-isobutylphenyl)propionamido)hexyl)-4,8-dioxo-1,3,6,2-dioxazaborolan-2-yl)-3-methylbutyl)amino)-1-oxo-3-phenylpropan-2-yl)pyrazine-2-carboxamide (18) Synthesis Scheme 18

[0138] Step 1: NaHCO3 (3.88 g, 46.18 mmol), KI (767 mg, 4.59 mmol) and compound 9-2 (3.86 g, 23.11 mmol) were added to a solution of compound 18-1 (1.0 g, 4.62 mmol) in DMF (10 mL). The mixture was stirred at room temperature for 16 hours. After the reaction was completed, the mixture was distributed in EtOAc (100 mL) and water (100 mL). The organic layer was washed with brine, dried over anhydrous Na2SO4 and concentrated. The residue was purified by silica gel column (eluted with 30% EtOAc in petroleum ether) to obtain compound 18-2 (1.24 g, yield: 69%).

[0139] Step 2: At room temperature, a mixture of compound 18-2 (700 mg, 1.80 mmol) in 4N HCl (EtOAc solution, 7 mL) and MeOH (0.5 mL) was stirred for 2 hours. After the reaction was completed, the mixture was concentrated to give compound 18-3 (622 mg, crude product), which was used directly in the next step without further purification.

[0140] Step 3: At room temperature, a solution of compound 18-3 (622 mg, crude product), compound 8-1 (371 mg, 1.79 mmol), DIPEA (581 mg, 4.50 mmol) and HATU (1.03 g, 2.70 mmol) in DMF (5 mL) was stirred for 3 hours. After the reaction was completed, the mixture was diluted with EtOAc (50 mL) and washed with water (50 mL x 2) and brine (50 mL). The organic layer was dried over anhydrous Na2SO4, filtered and concentrated. The crude product was purified by silica gel column (eluted with 30% EtOAc in petroleum ether) to give compound 18-4 (403 mg, yield after 2 steps: 46%). LCMS: m / z calculated for C 27 H 44 N2O5: 476.66; Obtained: 478.01 [M+H] + .

[0141] Step 4: At 0°C, NaOH (135 mg, 3.37 mmol) was added to a solution of compound 18-4 (403 mg, 0.845 mmol) in ethanol (4 mL) and H2O (2 mL), and the reactant was stirred at room temperature for 1 hour. The mixture was concentrated and adjusted to pH = 2 with 1N HCl at 0°C. The aqueous mixture was purified by reverse phase flash chromatography (C18 column, eluted with 50% acetonitrile aqueous solution, HCl conditions). The desired fraction was lyophilized to give compound 18-5 (181 mg, yield: 46%) as a white solid. LCMS: m / z calculated for C 23 H 36 N2O5: 420.55; obtained: 421.76 [M+H] + .

[0142] Step 5: At 120°C, a mixture of compound 18-5 (178 mg, 0.389 mmol) and compound 9-7 (149 mg, 0.388 mmol) in toluene (3 mL) was stirred for 16 hours. After the reaction was completed, the mixture was concentrated. The crude product was purified by pre-TLC (acetonitrile: dichloromethane = 1: 3) to obtain compound 18 (65 mg, yield: 21%) as a white solid. 1HNMR (400MHz, DMSO-d6) δ9.07(d,J=1.4Hz,1H),8.90(d,J=8.4Hz,1H),8.86(d,J=2.5Hz,1H),8.72(dd,J=2.5,1.5Hz,1H),7.87(t,J=5.5Hz,1 H),7.32(d,J=9.8Hz,1H),7.29-7.22(m,4H),7.21-7.13(m,3H),7.05(d,J=8.0Hz,2H),4.67(td,J=8.4,6.4Hz,1H),4.16(d,J=17.4Hz,1H),4. 04(d,J=17.4Hz,1H),3.94(d,J=16.7Hz,1H),3.60-3.50(m,2H),3.46(d,J=16.7Hz,1H),3.09-2.95(m,6H),2.38(d,J=7.1Hz,2H),1.77(dt,J =13.5, 6.7Hz, 1H), 1.61-1.51 (m, 2H), 1.42-1.33 (m, 3H), 1.29 (d, J = 7.1Hz, 4H), 1.26-1.15 (m, 5H), 0.83 (td, J = 8.3, 6.4Hz, 12H). LCMS: m / z calculation C 42 H 57 BN6O7: 768.76; Obtained: 769.93 [M+H] + . Embodiment 19 N-((S)-1-(((R)-1-(6-(7-((S)-2-(4-isobutylphenyl)propionamido)heptyl)-4,8-dioxo-1,3,6,2-dioxazaborolan-2-yl)-3-methylbutyl)amino)-1-oxo-3-phenylpropan-2-yl)pyrazine-2-carboxamide (19) Synthesis Scheme 19

[0143] Step 1: At room temperature, a mixture of compound 8-1 (1 g, 4.84 mmol), NHS (7.27 mmol), DMAP (60 mg, 0.491 mmol) and EDCI (1.86 g, 9.73 mmol) in DCM (10 mL) was stirred for 16 hours. After the reaction was completed, the mixture was diluted with DCM (50 mL) and washed with 1N HCl (50 mL) and water (50 mL). The organic layer was dried over anhydrous Na2SO4, filtered and concentrated to give compound 19-1 (1.26 g, yield: 85%) as a white solid.

[0144] Step 2: To a solution of compound 19-2 (996 mg, 7.66 mmol) and DIPEA (987 mg, 7.65 mmol) in DCM (5 mL) was added a solution of compound 19-1 (1.16 g, 3.82 mmol) in DCM (6 mL) for 1 hour. After stirring the reactant at room temperature for 4 hours, the mixture was concentrated. The crude product was purified by reverse phase flash chromatography (C18 column, eluted with 80% MeOH aqueous solution, HCl conditions). The desired component was concentrated to give compound 19-3 (hydrochloride, 667 mg, yield: 49%) as a colorless oil. LCMS: calculated C 20 H 34 N2O: 318.51; Obtained: 319.88 [M+H] + .

[0145] Step 3: To a solution of compound 19-3 (665 mg, 2.08 mmol) in DMF (8 mL) was added NaHCO3 (1.75 g, 20.83 mmol), KI (346 mg, 2.08 mmol) and compound 9-2 (1.74 g, 10.41 mmol). The mixture was stirred at room temperature for 16 hours. After the reaction was completed, the mixture was partitioned between EtOAc (50 mL) and water (50 mL). The organic layer was washed with brine, dried over anhydrous Na2SO4 and concentrated. The residue was purified by silica gel column (eluted with 50% EtOAc in petroleum ether) to give compound 19-4 (629 mg, yield: 61%). LCMS: m / z calculated for C 28 H 46 N2O5: 490.69; Obtained: 491.94 [M+H] + .

[0146] Step 4: At 0°C, NaOH (204 mg, 5.1 mmol) was added to a solution of compound 19-4 (627 mg, 1.27 mmol) in EtOH (6 mL) and H2O (3 mL), and the reaction was stirred at room temperature for 1 hour. The mixture was concentrated and adjusted to pH = 2 with 1N HCl at 0°C. The aqueous mixture was purified by reverse phase flash chromatography (C18 column, eluted with 55% acetonitrile aqueous solution, HCl conditions). The desired fraction was lyophilized to give compound 19-5 (229 mg, yield: 38%) as a white solid. LCMS: calculated C 24 H 38 N2O5: 434.58; Obtained: 435.75 [M+H] + .

[0147] Step 5: At 120° C., a mixture of compound 19-5 (195 mg, 0.414 mmol) and compound 9-7 (159 mg, 0.414 mmol) in toluene (5 mL) was stirred for 17 hours. After the reaction was completed, the mixture was concentrated. The crude product was purified by pre-TLC (acetonitrile: dichloromethane=1:3) to obtain compound 19 (170 mg, yield: 52%) as a white solid. 1 HNMR (400MHz, DMSO-d6) δ9.07(d,J=1.5Hz,1H),8.90(d,J=8.4Hz,1H),8.86(d,J=2.5Hz,1H),8.72(q,J=1.8Hz,1H),7.86(t,J=5.6Hz,1H),7 .35-7.25(m,4H),7.24-7.20(m,2H),7.17(d,J=10.7Hz,2H),7.05(dd,J=8.2,2.0Hz,2H),4.68(td,J=8.3,5.6Hz,1H),4.17(d,J=17.4Hz,1H ),4.04(d,J=17.4Hz,1H),3.95(d,J=16.6Hz,1H),3.60-3.50(m,2H),3.47(d,J=17.0Hz,1H),3.10-2.97(m,6H),2.37(dd,J=7.2,2.5Hz,2H) ,1.78(ddd,J=13.2,6.6,2.2Hz,1H),1.56(dp,J=10.3,3.4Hz,2H),1.42-1.33(m,3H),1.31-1.11(m,11H),0.86-0.80(m,12H).LCMS:m / z Calculate C 43 H 59 BN6O7: 782.79; Obtained: 783.86 [M+H] + . Embodiment 20 N-((S)-1-(((R)-1-(6-(8-((S)-2-(4-isobutylphenyl)propionamido)octyl)-4,8-dioxo-1,3,6,2-dioxazaborolan-2-yl)-3-methylbutyl)amino)-1-oxo-3-phenylpropan-2-yl)pyrazine-2-carboxamide (20) Synthesis Scheme 20

[0148] Step 1: NaHCO3 (3.44 g, 40.94 mmol), KI (679 mg, 4.09 mmol) and compound 9-2 (3.42 g, 20.47 mmol) were added to a solution of compound 20-1 (1.0 g, 4.09 mmol) in DMF (10 mL). The mixture was stirred at room temperature for 16 hours. After the reaction was completed, the mixture was distributed in EtOAc (100 mL) and water (100 mL). The organic layer was washed with brine, dried over anhydrous Na2SO4 and concentrated. The residue was purified by silica gel column (eluted with 30% EtOAc in petroleum ether) to obtain compound 20-2 (1.25 g, yield: 69%).

[0149] Step 2: A mixture of compound 20-2 (700 mg, 1.68 mmol) in 4N HCl (EtOAc solution, 7 mL) and MeOH (0.5 mL) was stirred at room temperature for 2 hours. After the reaction was completed, the mixture was concentrated to give compound 20-3 (637 mg, crude product), which was used directly in the next step without further purification.

[0150] Step 3: A solution of compound 20-3 (637 mg, crude product from step 2), compound 8-1 (346 mg, 1.67 mmol), DIPEA (542 mg, 4.20 mmol) and HATU (958 mg, 2.52 mmol) in DMF (5 mL) was stirred at room temperature for 16 hours. After the reaction was completed, the mixture was diluted with EtOAc (50 mL) and washed with water (50 mL x 2) and brine (50 mL). The organic layer was dried over anhydrous Na2SO4, filtered and concentrated. The crude product was purified by silica gel column (eluted with 30% EtOAc in petroleum ether) to give compound 20-4 (362 mg, yield after 2 steps: 42%). LCMS: m / z calculated for C 29 H 48 N2O5: 504.71; Obtained: 506.07 [M+H] + .

[0151] Step 4: At 0°C, NaOH (114 mg, 2.85 mmol) was added to a solution of compound 20-4 (360 mg, 0.713 mmol) in EtOH (4 mL) and H2O (2 mL), and the reaction was stirred at room temperature for 1 hour. The mixture was concentrated and adjusted to pH = 2 with 1N HCl at 0°C. The aqueous mixture was purified by reverse phase flash chromatography (C18 column, eluted with 50% acetonitrile aqueous solution, HCl conditions). The desired fraction was lyophilized to give compound 20-5 (247 mg, yield: 71%) as a white solid. LCMS: m / z calculated for C 25 H40 N2O5: 448.60; Obtained: 449.95 [M+H] + .

[0152] Step 5: At 120° C., a mixture of compound 20-5 (178 mg, 0.367 mmol) and compound 9-7 (141 mg, 0.366 mmol) in toluene (3 mL) was stirred for 16 hours. After the reaction was completed, the mixture was concentrated. The crude product was purified by pre-TLC (acetonitrile: dichloromethane=1:3) to obtain compound 20 (50 mg, yield: 17%) as a white solid. 1 HNMR (400MHz, DMSO-d6) δ9.07(d,J=1.5Hz,1H),8.90(d,J=8.5Hz,1H),8.86(d,J=2.5Hz,1H),8.73(t,J=1.9Hz,1H),7.85(t,J=5.6Hz,1H),7.3 2(d,J=9.7Hz,1H),7.29-7.23(m,4H),7.23-7.17(m,3H),7.05(d,J=7.8Hz,2H),4.68(td,J=8.7,5.8Hz,1H),4.17(d,J=17.4Hz,1H),4.04(d,J =17.4Hz,1H),3.95(d,J=16.6Hz,1H),3.60-3.51(m,2H),3.48(d,J=16.6Hz,1H),3.08-2.97(m,6H),2.38(d,J=7.1Hz,2H),1.78(dt,J=13.5,6 .7Hz,1H),1.61-1.52(m,2H),1.37(dd,J=21.4,4.9Hz,3H),1.28(d,J=7.1Hz,4H),1.26-1.17(m,9H),0.83(q,J=8.5,7.5Hz,12H).LCMS: m / z calculation C 44 H 61 BN6O7: 796.82; Obtained: 797.99 [M+H] + . Embodiment 21 N-((S)-1-(((R)-1-(6-(4-((S)-2-(4-isobutylphenyl)propionamido)methyl)cyclohexyl)-4,8-dioxo-1,3,6,2-dioxazaborolan-2-yl)-3-methylbutyl)amino)-1-oxo-3-phenylpropan-2-yl)pyrazine-2-carboxamide (21) Synthesis Scheme 21

[0153] Step 1: At room temperature, a mixture of compound 21-1 (700 mg, 3.07 mmol), 10w% Pd / C (350 mg) and ammonium hydroxide (28%, 9.5 mL) in MeOH (10 mL) was purged with hydrogen 3 times and stirred in a hydrogen environment for 16 hours. The mixture was concentrated to give a colorless oily compound 21-2 (746 mg, crude product), which was used directly in the next step without further purification.

[0154] Step 2: NaHCO3 (1.39 g, 16.54 mmol), KI (275 mg, 1.65 mmol) and compound 9-2 (1.38 g, 8.26 mmol) were added to a DMF (5 mL) solution of compound 21-2 (380 mg, 1.66 mmol). The mixture was stirred at room temperature for 16 hours. After the reaction was completed, the mixture was distributed in EtOAc (50 mL) and water (50 mL). The organic layer was washed with brine, dried over anhydrous Na2SO4 and concentrated. The residue was purified by silica gel column (eluted with a petroleum ether solution of 20% EtOAc) to obtain compound 21-3 (490 mg, yield after 2 steps: 73%).

[0155] Step 3: A mixture of compound 21-3 (480 mg, 1.19 mmol) in 4N HCl (EtOAc solution, 5 mL) was stirred at room temperature for 2 hours. After the reaction was completed, the mixture was concentrated to give compound 21-4 (450 mg, crude product), which was used in the next step without further purification.

[0156] Step 4: At room temperature, a solution of compound 21-4 (450 mg), compound 8-1 (297 mg, 1.43 mmol), DIPEA (390 mg, 3.02 mmol) and HATU (684 mg, 1.79 mmol) in DMF (5 mL) was stirred for 16 hours. After the reaction was completed, the mixture was diluted with EtOAc (50 mL) and washed with water (50 mL x 2) and brine (50 mL). The organic layer was dried over anhydrous Na2SO4, filtered and concentrated. The crude product was purified by silica gel column (eluted with 30% EtOAc in petroleum ether) to obtain compound 21-5 (339 mg, yield: 58%). 1HNMR(400MHz,Chloroform-d)δ7.17(d,J=7.1Hz,2H),7.11(d,J=7.6Hz,2H),5.30(s,1H),4.14 (q,J=7.1Hz,4H),3.52(s,4H),3.49(d,J=7.9Hz,1H),2.99(q,J=6.0Hz,2H),2.57(t,J=11.6Hz , 1H), 2.45 (d, J = 7.0 Hz, 2H), 1.83 (d, J = 8.2 Hz, 3H), 1.76 (s, 1H), 1.60 (d, J = 12.7 Hz, 2H), 1.50 (d, J = 7.1 Hz, 3H), 1.25 (t, J = 7.1 Hz, 8H), 1.11 (q, J = 12.0 Hz, 2H), 0.91-0.87 (m, 6H). LCMS: m / z calculated for C 28 H 44 N2O5: 488.67; Obtained: 489.75 [M+H] + .

[0157] Step 5: At 0°C, NaOH (110 mg, 2.75 mmol) was added to a solution of compound 21-5 (337 mg, 0.689 mmol) in ethanol (3 mL) and H2O (1.5 mL). The reaction was stirred at room temperature for 1 hour. The mixture was concentrated and adjusted to pH = 2 with 1N HCl at 0°C. The aqueous mixture was purified by reverse phase flash chromatography (C18 column, eluted with 55% acetonitrile aqueous solution, HCl conditions). The desired component was lyophilized to obtain compound 21-6 (207 mg, yield: 64%) as a white solid.

[0158] Step 6: At 120°C, a mixture of compound 21-6 (155 mg, 0.33 mmol) and compound 9-7 (127 mg, 0.33 mmol) in toluene (3 mL) was stirred for 16 hours. After the reaction was completed, the mixture was concentrated. The crude product was purified by pre-TLC (acetonitrile: dichloromethane = 1: 3) to obtain compound 21 (115 mg, yield: 44%) as an off-white solid. 1HNMR(400MHz,DMSO-d6)δ9.08(d,J=1.4Hz,1H),8.89-8.85(m,2H),8.73(dd,J=2.5 ,1.5Hz,1H),7.92(t,J=5.9Hz,1H),7.46(d,J=9.5Hz,1H),7.32-7.28(m,2H),7.25 (t,J=7.5Hz,2H),7.21(d,J=8.0Hz,2H),7.19-7.15(m,1H),7.05(d,J=8.0Hz,2H), 4.72-4.64(m,1H),4.31(d,J=17.9Hz,1H),3.84(dd,J=17.0,6.7Hz,2H),3.62-3.5 2(m,2H),3.25(d,J=16.4Hz,2H),3.07(d,J=7.6Hz,2H),2.86(t,J=6.5Hz,2H),2.3 9(d,J=7.1Hz,2H),1.77(dt,J=13.7,6.8Hz,1H),1.74-1.62(m,3H),1.61-1.36(m, 6H),1.31(d,J=7.1Hz,4H),1.16(ddd,J=13.7,10.4,2.9Hz,1H),1.09-0.97(m,1H) ,0.86(d,J=6.7Hz,3H),0.83(d,J=6.6Hz,6H),0.78(d,J=6.4Hz,3H).LCMS:m / z Calculate C 43 H 57 BN6O7: 780.77; Obtained: 782.00 [M+H] + . Embodiment 22 N-((S)-1-(((R)-3-methyl-1-(6-(4-((S)-2-(4-(2-(methyl-d3)propyl-3,3,3-d3)phenyl)propionamido)butyl)-4,8-dioxo-1,3,6,2-dioxazaborolan-2-yl)butyl)amino)-1-oxo-3-phenylpropan-2-yl)pyrazine-2-carboxamide (22) Synthesis Scheme 22

[0159] Step 1: NaH (60% in mineral oil, 9.35 g, 233 mmol) was added to a solution of compound 22-2 (63 g, 281 mmol) in anhydrous THF (250 mL) in batches at 0 ° C in a nitrogen atmosphere over 10 minutes. After stirring at 0 ° C for 1 hour, deuterated acetone 22-1 (10 g, 156 mmol) was slowly added thereto over 15 minutes. The reaction was then warmed to room temperature and stirred for another 6 hours. The mixture was quenched with saturated NH4Cl solution (300 mL) and extracted with isopropyl ether (300 mL x 2). The organic layer was dried over anhydrous Na2SO4, filtered and concentrated to give compound 22-3 (22 g, crude product), which was used directly in the next step without further purification.

[0160] Step 2: At 0°C, 2N LiOH (270mL, 540mmol) was added to a mixture of compound 22-3 (22g, crude product from step 1) in EtOH (150mL). The reactant was stirred at room temperature for 16 hours. The resulting mixture was cooled to 0°C and adjusted to pH=2 with a 6NHCl aqueous solution. The mixture was extracted with isopropyl ether (200mLx 2). The organic layer was dried with anhydrous Na2SO4, filtered and concentrated to obtain compound 22-4 (13.4g, 80% yield after 2 steps), which was directly used in the next step without further purification.

[0161] Step 3: At 0°C, to a solution of compound 22-4 (3 g, 28.2 mmol), compound 22-5 (6.92 g, 42.4 mmol) and DMAP (170 mg, 1.39 mmol) in DCM (50 mL) was added DCC (8.75 g, 42.4 mmol). The reactant was stirred at room temperature for 15 hours. The mixture was concentrated and purified by silica gel column (eluted with 20% EtOAc in petroleum ether) to give compound 22-6 (3.2 g, yield: 45%) as a white solid.

[0162] Step 4: A mixture of compound 22-6 (2.3 g, 9.15 mmol), compound 22-7 (330 mg, 1.84 mmol) and B2(Pin)2 (4.65 g, 18.3 mmol) in anhydrous PhCF3 (23 mL) was purged with nitrogen three times and stirred at 110°C for 20 hours. The mixture was concentrated and purified by silica gel column (eluted with 3% EtOAc in petroleum ether) to give compound 22-8 (470 mg, yield: 27 1 H NMR (400MHz, DMSO-d6) δ4.98 (s, 1H), 1.19 (s, 12H).

[0163] Step 5: Under nitrogen, a mixture of compound 22-8 (550 mg, 2.92 mmol), compound 22-9 (736 mg, 3.21 mmol), Pd (PPh 3 ) 4 (168 mg, 0.145 mmol) and K 2 CO 3 (1.2 g, 8.68 mmol) in dioxane (6 mL) was stirred at 120 ° C for 16 hours. After the reaction was completed, the mixture was filtered and concentrated. The crude product was purified by reverse phase flash chromatography (C18 column, eluted with 50% acetonitrile aqueous solution, TFA conditions). The desired component was freeze-dried to obtain compound 22-10 (460 mg, yield: 75%) as a colorless syrup.

[0164] Step 6: A mixture of compound 22-10 (460 mg, 2.18 mmol) and PtO2 (50 mg, 0.22 mmol) in MeOH (5 mL) was stirred under a hydrogen atmosphere for 16 hours. After the reaction was completed, the mixture was filtered through celite and concentrated to give compound 22-11 (350 mg, yield: 75%) as a colorless syrup. 1 H NMR (400MHz, DMSO-d6) δ7.18(d,J=7.8Hz,2H),7.08(d,J=7.8Hz,2H),3.60(q,J= 7.1Hz, 1H), 2.40 (d, J = 7.2Hz, 2H), 1.76 (t, J = 7.2Hz, 1H), 1.32 (d, J = 7.1Hz, 3H).

[0165] Step 7: A solution of compound 13-2 (200 mg, 0.673 mmol), compound 22-11 (95 mg, 0.447 mmol), DIPEA (260 mg, 2.01 mmol) and HATU (300 mg, 0.789 mmol) in DMF (3 mL) was stirred at room temperature for 16 hours. After the reaction was completed, the mixture was diluted with EtOAc (30 mL) and washed with water (30 mL x 2) and brine (30 mL). The organic layer was dried over anhydrous Na2SO4, filtered and concentrated. The crude product was purified by silica gel column (eluted with 20% EtOAc in petroleum ether) to give compound 22-12 (106 mg, yield: 52%). LCMS: m / z calculated C 25 H 34 D6N2O5:454.64; Obtained:455.99[M+H] + .

[0166] Step 8: At 0°C, 2NNaOH (0.44mL, 0.88mmol) was added to a solution of compound 22-12 (100mg, 0.220mmol) in EtOH (2mL), and the reaction was stirred at room temperature for 1 hour. The mixture was concentrated and adjusted to pH=2 with 1NHCl at 0°C. The aqueous mixture was purified by reverse phase flash chromatography (C18 column, eluted with 35% acetonitrile aqueous solution, HCl conditions). The desired component was lyophilized to obtain compound 22-13 (68mg, yield: 75%) as a white solid.

[0167] Step 9: At 120°C, a mixture of compound 22-13 (60 mg, 0.151 mmol) and compound 9-7 (60 mg, 0.156 mmol) in toluene (3 mL) was stirred for 16 hours. After the reaction was completed, the mixture was concentrated. The crude product was purified by pre-TLC (acetonitrile: dichloromethane = 1: 3) to obtain compound 22 (26 mg, yield: 23%) as an off-white solid. 1 HNMR (400MHz, DMSO-d6) δ9.12(s,1H),8.90(s,2H),8.76(s,1H),8.00(s,1H),7.38(d,J=9.7Hz,1H),7.27(ddt,J=24 .5,17.1,7.2Hz,7H),7.09(d,J=7.7Hz,2H),4.72(d,J=7.9Hz,1H),4.10(q,J=17.3Hz,2H),3.95(d,J=16.6Hz,1H),3 .58(d,J=8.2Hz,2H),3.50(d,J=17.1Hz,1H),3.17-3.01(m,6H),2.41(d,J=7.0Hz,2H),1.78(d,J=8.4Hz,1H),1.66- 1.54(m,2H),1.43(d,J=12.5Hz,4H),1.35(d,J=6.8Hz,3H),1.20(s,1H),0.87(dd,J=16.0,6.7Hz,6H).LCMS:m / z Calculate C 40 H 47 D6BN6O7:746.75; obtained:747.5[M+H] + . Embodiment 23 N-(4-((4-amino-2-butyl-1H-imidazo[4,5-c]quinolin-1-yl)oxy)butyl)-4-(4-iodophenyl)butanamide (23) Synthesis Scheme 23

[0168] Step 1: To an ice-cold solution of compound 23-1 (10.0 g, 52.8 mmol) in anhydrous THF (200 mL) was added PPh3 (20.8 g, 79.3 mmol), followed by a solution of CBr4 (26.3 g, 79.3 mmol) in THF (100 mL). The reactant was warmed to room temperature and stirred for 2 hours. The mixture was filtered and concentrated. The residue was purified by silica gel column (eluted with 20% EtOAc in petroleum ether) to give compound 23-2 (12 g, 90%) as a colorless oil.

[0169] Step 2: At room temperature, a mixture of compound 23-3 (500 mg, 1.95 mmol), K2CO3 (540 mg, 3.90 mmol) and compound 23-2 (590 mg, 2.34 mmol) in DMF (5 mL) was stirred for 16 hours. The resulting mixture was filtered and the filter cake was washed with EtOAc (50 mL). The organic phase was washed with cold water (50 mL) and brine (50 mL). The organic layer was dried over anhydrous Na2SO4, filtered and concentrated. The crude product was purified by silica gel column (eluted with 5% MeOH in dichloromethane) to obtain compound 23-4 (585 mg, yield: 70%) as a light yellow solid.

[0170] Step 3: 4N HCl (EtOAc solution, 2.5 mL) was added to a solution of compound 23-4 (585 mg, 1.36 mmol) in EtOAc (2 mL) and MeOH (0.5 mL). After stirring the reaction at room temperature for 1 hour, the mixture was concentrated to give compound 23-5 (450 mg, yield: 90%) as a white solid.

[0171] Step 4: At room temperature, a mixture of compound 23-5 (80 mg, 0.275 mmol), DIPEA (56 mg, 0.434 mmol), DMAP (3 mg, 0.024 mmol), EDCI (65 mg, 0.340 mmol) and compound 1-2 (80 mg, 0.220 mmol) in DCM (5 mL) was stirred for 1 hour. After the reaction was completed, the mixture was concentrated. The crude product was purified by pre-HPLC (eluted with 60% acetonitrile aqueous solution, HCl conditions) to obtain compound 23 (60 mg, yield: 45%) as a white solid. 1H NMR (500MHz, DMSO-d6) δ8.19(d,J=8.1Hz,1H),7.90(d,J=5.4Hz,1H),7.84(d,J=8.4Hz,1H),7.77-7.72 (m,1H),7.64-7.56(m,3H),7.00(d,J=8.1Hz,2H),4.41(t,J=6.6Hz,2H),3.15(q,J=6.5Hz,2H),3.00(t ,J=7.6Hz,2H),2.52(d,J=7.9Hz,2H),2.07(t,J=7.4Hz,2H),1.92(t,J=7.5Hz,2H),1.82(t,J=7.6Hz,2 H),1.77(t,J=7.5Hz,2H),1.71-1.62(m,2H),1.42(q,J=7.4Hz,2H),0.93(t,J=7.4Hz,3H).LCMS: m / z calculation C 28 H 34 IN5O2: 599.52; Obtained: 600.82 [M+H] + . Embodiment 24 N-(4-((4-amino-2-butyl-7-(dimethylphosphoryl)-1H-imidazo[4,5-c]quinolin-1-yl)oxy)butyl)-4-(4-iodophenyl)butyramide (24) Synthesis Scheme 24

[0172] Step 1: A mixture of compound 24-1 (19 mg, 0.048 mmol), compound 1-2 (28 mg, 0.0965 mmol), EDCI (36 mg, 0.188 mmol), DMAP (1 mg, 0.008 mmol) and TEA (10 mg, 0.099) in DCM (0.5 mL) and DMF (0.5 mL) was stirred at room temperature for 1 hour. After the reaction was completed, the resulting mixture was filtered and purified by pre-HPLC (eluted with 70% acetonitrile in water; HCl conditions). The components were lyophilized to give compound 24 (11.2 mg, yield: 35.8%) as a yellow oil. LCMS: m / z calculated for C 30 H 39 IN5O3P: 675.55; Obtained: 676.2 [M+H] + . Embodiment 25 N-(2-((2-((4-((4-amino-2-butyl-1H-imidazo[4,5-c]quinolin-1-yl)oxy)butyl)(3-(dimethylamino)propyl)amino)-3,4-dioxocyclobutyl-1-en-1-yl)amino)ethyl)-4-(4-iodophenyl)butanamide (25) Synthesis Scheme 25

[0173] Step 1: Add EDCI (395 mg, 2.06 mmol) and compound 9-1 (243 mg, 1.51 mmol) to a solution of compound 1-2 (400 mg, 1.37 mmol) in DCM (8 mL). After stirring at room temperature for 2 hours, TLC showed that compound 1-2 was consumed. The reaction mixture was diluted with EtOAc and washed with 1N HCl and saturated sodium carbonate and brine. The organic layer was dried over anhydrous Na2SO4, filtered and concentrated under reduced pressure to obtain a colorless oily compound 25-1 (330 mg), which was used directly in the next step. TLC (petroleum ether: EtOAc / 1:1): R f (Compound 9-1) = 0.55; R f (Compound 25-1) = 0.37.

[0174] Step 2: A mixture of crude compound 25-1 (330 mg) in HCl / EtOAc (4M, 10 mL) was stirred at room temperature for 30 minutes. After the reaction was completed, the mixture was concentrated. The residue was redissolved in EtOAc and washed with saturated Na2CO3 solution. The organic layer was dried over anhydrous Na2SO4, filtered and concentrated under reduced pressure to obtain a colorless oily compound 25-2 (225 mg), which was used directly in the next step. TLC (petroleum ether: EtOAc / 1:1) R f (Compound 25-1) = 0.37; TLC (DCM: MeOH / 10: 1): R f (Compound 25-2) = 0.46.

[0175] Step 3: At 0°C, a solution of compound 25-2 (225 mg, crude product) in MeOH (2 mL) was added dropwise to a solution of compound 25-3 (154 mg, 0.905 mmol) in MeOH (5 mL). After stirring at room temperature for 4 hours, TLC showed that compound 25-2 was consumed and a new spot with lower polarity was formed. The reaction mixture was evaporated in vacuo and purified by a silica gel column (eluted with a 5% MeOH solution in DCM) to give compound 25-4 (230 mg, yield after 3 steps: 36%) as a white solid. TLC (DCM: MeOH / 10: 1): Rf (Compound 25-2) = 0.46, R f (Compound 25-4) = 0.58.

[0176] Step 4: A mixture of compound 25-4 (67 mg, 0.145 mmol), compound 25-5 (40 mg, 0.970 mmol) and DIPEA (40 mg, 0.396 mmol) in acetonitrile (2 mL) and DCM (2 mL) was stirred at room temperature for 24 hours. LC-MS showed that compound 25-5 was consumed, and a new peak with the desired m / z was detected by LCMS. The reaction mixture was concentrated, redissolved in acetonitrile and water, and purified by HPLC (C18 column, eluted with acetonitrile / H2O, HCl conditions). The desired component was lyophilized to obtain compound 25 (8 mg, yield: 10%) as a white powder. 1 HNMR (400MHz, Methanol-d4) δ8.12(d,J=8.1Hz,1H),7.68(d,J=8.4Hz,1H),7.53(t,J=7.8Hz,1H),7.46(d,J=7.9Hz,2 H),7.36(t,J=7.7Hz,1H),6.86(d,J=7.9Hz,2H),4.33(s,2H),3.75(t,J=5.8Hz,2H),3.41(s,2H),3.35(d,J=2.4Hz,2H ),2.99(t,J=7.6Hz,2H),2.47(t,J=7.8Hz,2H),2.39(d,J=7.1Hz,2H),2.27(s,6H),2.16(d,J=7.7Hz,2H),1.98(d,J=9 .8Hz, 2H), 1.85 (dq, J=23.9, 7.5Hz, 8H), 1.49 (d, J=7.6Hz, 2H), 1.30-1.26 (m, 2H), 1.01 (t, J=7.4Hz, 3H). LCMS: m / z calculation C 39 H 51 IN8O4: 822.79; yield: 823.4 [M+H] + . Embodiment 26 (S)-N-(2-((2-((4-((4-amino-2-butyl-1H-imidazo[4,5-c]quinolin-1-yl)oxy)butyl)amino)-3,4-dioxocyclobutyl-1-en-1-yl)amino)ethyl)-2-(4-isobutylphenyl)propanamide (26) Synthesis Scheme 26

[0177] Step 1: Compound 9-1 (1 g, 6.24 mmol) in anhydrous MeOH (10 mL) solution was added dropwise to a solution of compound 25-3 (1.06 g, 6.23 mmol) in anhydrous MeOH (10 mL). The mixture was stirred at room temperature for 1 hour. After the reaction was completed, the mixture was diluted with EtOAc (50 mL), washed with water (50 mL) and brine (50 mL). The organic layer was dried over anhydrous Na2SO4, filtered and concentrated. The crude product was purified by column chromatography (eluted with 40% EtOAc in petroleum ether) to obtain compound 26-1 (1.63 g, yield: 97%) as a colorless oil.

[0178] Step 2: Compound 23-5 (339 mg, 1.03 mmol) and DIPEA (333 mg, 2.58 mmol) in anhydrous MeOH (4 mL) solution was added dropwise to compound 26-1 (440 mg, 1.55 mmol) in anhydrous MeOH (3 mL). The mixture was stirred at room temperature for 3 hours. After the reaction was completed, the mixture was concentrated. The crude product was purified by reverse phase flash chromatography (C18 column, eluted with 60% acetonitrile aqueous solution, TFA conditions). The desired component was lyophilized to obtain compound 26-2 (TFA salt, 445 mg, yield: 63%) as a yellow solid.

[0179] Step 3: A mixture of compound 26-2 (445 mg, 0.65 mmol) in 20% TFA in DCM (3 mL) was stirred at room temperature for 1 hour. After the reaction was completed, the mixture was concentrated to remove the organic solvent to obtain compound 26-3 (420 mg, yield: 92%) as a light yellow syrup.

[0180] Step 4: A mixture of compound 26-3 (100 mg, 0.148 mmol), compound 8-1 (46 mg, 0.222 mmol), DMAP (2 mg, 0.016 mmol), DIPEA (57 mg, 0.442 mmol) and EDCI (42 mg, 0.220 mmol) in DMF (2 mL) was stirred at room temperature for 16 hours. After the reaction was completed, the mixture was filtered and purified by pre-HPLC (eluted with 50% acetonitrile aqueous solution, HCl conditions). The desired component was lyophilized to obtain compound 26 (40 mg, yield: 39%) as a white solid. 1H NMR (600MHz, DMSO-d6) δ8.20(dd,J=8.1,1.4Hz,1H),7.85-7.81(m,1H),7.74(ddd,J=8.4,7.2,1.3Hz,1H),7.62(t,J=7.7 Hz,1H),7.17(d,J=7.5Hz,2H),7.01(d,J=7.2Hz,2H),4.44(t,J=6.5Hz,2H),3.57-3.43(m,5H),3.28(d,J=7.0Hz,1H),3.1 2(dd,J=13.3,6.5Hz,1H),3.00(t,J=7.6Hz,2H),2.39-2.31(m,2H),2.01(s,2H),1.82(td,J=14.1,13.2,6.6Hz,4H),1.76 (d,J=4.4Hz,1H),1.43(q,J=7.4Hz,2H),1.29(d,J=7.0Hz,3H),0.93(t,J=7.4Hz,3H),0.81(d,J=6.6Hz,6H).LCMS: m / z calculation C 37 H 47 N7O4: 653.83; Obtained: 654.88 [M+H] + . Embodiment 27 (S)-N-(4-((4-amino-2-butyl-7-(dimethylphosphoryl)-1H-imidazo[4,5-c]quinolin-1-yl)oxy)butyl)-2-(4-isobutylphenyl)propanamide (27) Synthesis Scheme 27

[0181] Step 1: At room temperature, a mixture of compound 24-1 (60 mg, 0.148 mmol), compound 8-1 (46 mg, 0.223 mmol), DMAP (2 mg, 0.016 mmol), DIPEA (57 mg, 0.442 mmol) and EDCI (45 mg, 0.235 mmol) in DMF (2 mL) was stirred for 16 hours. After the reaction was completed, the mixture was filtered and purified by pre-HPLC (eluted with 45% acetonitrile aqueous solution, HCl conditions). The desired component was lyophilized to obtain compound 27 (24 mg, yield: 27%) as a white solid. 1H NMR (600MHz, DMSO-d6) δ8.29-8.24(m,2H),8.09(t,J=5.7Hz,1H),7.95(ddd,J=10.0,8.3,1.3Hz,1H ),7.23(d,J=8.1Hz,2H),7.05(d,J=8.1Hz,2H),4.39(t,J=6.6Hz,2H),3.60(s,1H),3.16(q,J=6.6Hz , 2H), 3.04-3.00 (m, 2H), 2.37 (d, J = 7.1 Hz, 2H), 1.91-1.82 (m, 4H), 1.77 (d, J = 13.5 Hz, 7H), 1.68-1.63 (m, 2H), 1.49-1.41 (m, 2H), 1.32 (d, J = 7.1 Hz, 3H), 0.96 (t, J = 7.4 Hz, 3H), 0.82 (s, 6H). LCMS: m / z calculated for C 33 H 46 N5O3P: 591.74; Obtained: 592.93 [M+H] + . Embodiment 28 (5-Fluoro-2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)methyl 4-(4-iodophenyl)butanoic acid methyl ester (28) Synthesis Scheme 28

[0182] Step 1: Compound 28-1 (1.3 g, 10.0 mmol) was dissolved in 37% formaldehyde solution (1.8 g, 22.2 mmol), and the mixture was stirred and refluxed at 60° C. for 4 hours. The mixture was concentrated to give compound 28-2 (1.5 g, yield: 93%) as a colorless oil, which was used directly in the next step without purification.

[0183] Step 2: Oxalyl chloride (0.50mL, 5.82mmol) and a catalytic amount of DMF were added to a solution of compound 1-2 (200mg, 0.69mmol) in dichloromethane (20mL). The resulting mixture was stirred at 45°C for 1 hour. The mixture was azeotroped with dichloromethane under reduced pressure 3 times to obtain a crude chloride intermediate. The chloride was redissolved in anhydrous dichloromethane (5mL) and added to a solution of compound 28-2 (220mg, 1.38mmol), DMAP (8mg, 0.07mmol) and TEA (100uL, 0.69mmol) in anhydrous dichloromethane (10mL) at room temperature. The resulting mixture was stirred and refluxed at 50°C for 10 hours. After concentrating the mixture, the residue was purified by a silica gel column (eluted with a 50% EtOAc petroleum ether solution) to obtain compound 28 (72mg, yield: 26%) as a white solid. 1 H NMR (400MHz, DMSO-d6) δ12.00(s,1H),8.14(d,J=6.4Hz,1H),7.68-7.56(m,2H),7.01(d,J=7 .8Hz,2H),5.56(s,2H),2.54(d,J=7.6Hz,2H),2.33(t,J=7.3Hz,2H),1.78(t,J=7.5Hz,2H). Embodiment 29 (5-fluoro-2,4-dioxopyrimidine-1,3(2H,4H)-diyl)bis(methylene)bis(4-(4-iodophenyl)butyric acid methyl ester) (29) Synthesis Scheme 29

[0184] Step 1: A suspension of compound 28-1 (1.0 g, 7.69 mmol) in 37% formaldehyde solution (2 mL) was stirred for 4 hours at 60° C. The reaction mixture was concentrated to give compound 29-1 (1.5 g) as a colorless oil, which was used in the next step without purification.

[0185] Step 2: At room temperature, oxalyl chloride (2.18g, 17.21mmol) and a catalytic amount of DMF were added to a DCM (5mL) solution of compound 1-2 (500mg, 1.73mmol). At 45°C, the resulting mixture was stirred for 1 hour. After compound 1-2 was consumed, the mixture was concentrated. The residue was redissolved in DCM (10mL), and compound 29-1 (250mg, 1.32mmol), DMAP (16mg, 0.131mmol) and TEA (650mg, 6.44mmol) were added to the solution at room temperature. The resulting mixture was stirred at 50°C for 16 hours. After the reaction was completed, the mixture was concentrated. The residue was purified by silica gel column purification (eluted with a petroleum ether solution of 2% EtOAc) and further purified by reverse phase flash chromatography (C18 column, eluted with acetonitrile and water, TFA conditions) to obtain compound 29 (70mg, yield after 2 steps: 7%), which was a white solid. 1 HNMR (400MHz, DMSO-d6) δ8.29 (dq, J=6.3, 3.8, 3.1Hz, 1H), 7.61 (ddq, J=6.4, 4.1, 2.4Hz, 4H), 6.99 (dt, J=8.1, 3.4Hz, 4H), 5.82-5.75(m,2H),5.67-5.58(m,2H),2.52(d,J=5.9Hz,4H),2.35-2.23(m,4H),1.76(dq,J=12.2,7.2Hz,4H).LCMS: m / z calculation C 26 H 25 FI2N2O6:734.30; obtained:757.33.[M+Na] + . Embodiment 30 (2aR,4S,4aS,6R,9S,11S,12S,12aR,12bS)-12b-acetoxy-9-(((2R,3S)-3-((tert-butoxycarbonyl)amino)-2-((4-(4-iodophenyl)butanoyl)oxy)-3-phenylpropanoic acid chloride)oxy)-4,6,11-trihydroxy-4a,8,13,13-tetramethyl-5-oxo-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-1H-7,11-methylcyclodecan[3,4]benzo[1,2-b]oxa-12-ylbenzoate (30) Synthesis Scheme 30

[0186] Step 1: At -10 ° C, DCC (77 mg, 0.37 mmol) and DMAP (45 mg, 0.37 mmol) were added to a solution of compound 30-1 (200 mg, 0.25 mmol) and 4-(p-iodophenyl)butyric acid 1-2 (79 mg, 0.27 mmol) in dichloromethane (16 mL). After stirring for 3 hours at -10 ° C, the mixture was filtered, diluted with EtOAc (50 mL), and washed with water (50 mL) and brine (50 mL). The organic layer was dried over anhydrous Na2SO4 and concentrated. The residue was purified by silica gel column (eluted with 40% EtOAc in petroleum ether) to obtain compound 30 (115 mg, yield: 43%) as a white solid. 1 H NMR(400MHz,Chloroform-d)δ8.16(d,J=7.7Hz,2H),7.68-7.60(m,3H),7.55(t,J=7.5Hz ,2H),7.43(t,J=7.5Hz,2H),7.37-7.31(m,3H),6.90(d,J=7.8Hz,2H),6.30(s,1H),5.74( d,J=7.0Hz,1H),5.52(s,1H),5.45-5.34(m,2H),5.26(s,1H),5.01(d,J=9.4Hz,1H),4.37 (d,J=8.5Hz,1H),4.31(q,J=8.3Hz,1H),4.24(d,J=6.4Hz,2H),4.20-4.13(m,1H),3.99(d ,J=7.0Hz,1H),2.64(dt,J=15.4,8.1Hz,1H),2.54(t,J=7.6Hz,3H),2.49(s,3H),2.38(dp ,J=23.3,8.3Hz,4H),2.22(s,1H),2.09(d,J=1.7Hz,2H),2.01(s,3H),1.90(q,J=8.4,7.7 Hz,4H),1.80(s,3H),1.69(s,1H),1.63(d,J=1.7Hz,3H),1.54(d,J=7.5Hz,1H),1.38(s,1 1H),1.32(d,J=1.9Hz,1H),1.30(d,J=1.7Hz,2H),1.28(s,4H),1.17(s,4H).LCMS: m / z calculation C 53 H 62 INO 15 :1079.98; obtained:1102.7[M+Na] + . Embodiment 31 N 2-(4-(2-(2-amino-4-oxo-4,7-dihydro-3H-pyrrolo[2,3-d]pyrimidin-5-yl)ethyl)benzoyl)-N 5 -(2-(4-(4-iodophenyl)butyramido)ethyl)-L-glutamine (31) Synthesis Scheme 31

[0187] Step 1: At 0°C, EDCI (362 mg, 1.89 mmol), triethylamine (0.74 mL, 5.16 mmol) and DMAP (20 mg, 0.17 mmol) were added to a solution of compound 31-1 (520 mg, 1.41 mmol) and compound 25-2 (574 mg, 1.89 mmol) in dichloromethane (20 mL). The reactant was stirred at room temperature for 2 hours, and the mixture was diluted with dichloromethane (100 mL), washed with 1N HCl (100 mL) and brine (100 mL). The organic layer was dried over anhydrous Na2SO4, filtered and concentrated to give compound 31-2 (740 mg, yield: 85%), which was used in the next step without further purification.

[0188] Step 2: A mixture of compound 31-2 (400 mg, 0.65 mmol) in 4N HCl (EtOAc solution, 5 mL) was stirred at room temperature for 1 hour to form a white precipitate which was filtered. The solid was dried in vacuo to give compound 31-3 (hydrochloride salt, 200 mg, yield: 62%).

[0189] Step 3: At room temperature, a solution of compound 31-4 (200 mg, 0.67 mmol), DMAP (8 mg, 0.07 mmol), NHS (115 mg, 1.00 mmol) and EDCI (128 mg, 0.67 mmol) in anhydrous DMSO (3 mL) was stirred for 1 hour. Compound 31-3 (200 mg, 0.40 mmol) and Et3N (483 μL, 3.35 mmol) were added. After stirring at room temperature for 12 hours, the mixture was purified by prep-HPLC (eluted with 60% acetonitrile aqueous solution, HCl conditions) to obtain compound 31 (67 mg, yield: 22%) as a light pink solid. 1H NMR (400MHz, DMSO-d6) δ10.71(s,1H),8.60(d,J=7.7Hz,1H),7.89(s,1H),7.79(d,J=7.7Hz,3H),7.61(d,J=7.9Hz,2H),7.29(d,J=7.9Hz,2H),7.00( d,J=8.0Hz,2H),6.34(s,1H),6.27(s,1H),4.32(d,J=10.2Hz,1H),3.12-2 .80(m,12H),2.11(dt,J=69.0,7.7Hz,7H),1.79-1.67(m,2H).LCMS:m / z Calculate C 32 H 36 IN7O6:741.59; yield:742.4.[M+H] + . Embodiment 32 (S)-2-(4-(2-(2-amino-4-oxo-4,7-dihydro-3H-pyrrolo[2,3-d]pyrimidin-5-yl)ethyl)benzamido)-5-(2-(4-(4-iodophenyl)butyramido)ethoxy)-5-oxopentanoic acid (32) Synthesis Scheme 32

[0190] Step 1: EDCI (658 mg, 3.44 mmol) and DMAP (21 mg, 0.172 mmol) were added to a mixture of acid 1-2 (500 mg, 1.72 mmol) and NHS (295 mg, 2.56 mmol) in DCM (10 mL), and the mixture was stirred at room temperature for 2 hours. The reaction mixture was diluted with DCM (50 mL) and washed with 1N HCl (50 mL). The organic layer was dried over anhydrous Na2SO4, filtered and concentrated to give a crude NHS activated ester as a white solid. A THF (5 mL) solution of NHS activated ester was added dropwise to a DMF (5 mL) solution of compound 32-1 (126 mg, 2.06 mmol) and DIEA (340 μL, 2.06 mmol). The reaction mixture was stirred at room temperature for 16 hours. The resulting reaction mixture was diluted with EtOAc (50 mL) and washed with 1N HCl (50 mL) and brine. The organic layer was dried over anhydrous Na 2 SO 4 , filtered and concentrated to give compound 32-2 (495 mg, yield: 86%) as a white solid, which was used directly in the next step without further purification.

[0191] Step 2: At 0°C, EDCI (218 mg, 1.14 mmol) was added to a DCM (10 mL) solution of DMAP (7 mg, 0.06 mmol), compound 32-2 (190 mg, 0.57 mmol) and compound 31-1 (260 mg, 0.86 mmol). After stirring at room temperature for 2 hours, the mixture was diluted with DCM (100 mL), washed with 1N HCl (50 mL) and brine (50 mL). The organic layer was dried, filtered and concentrated over Na2SO4 to give compound 32-3 (845 mg, yield: 85%), which was used directly in the next step without further purification.

[0192] Step 3: Compound 32-3 (400 mg, 0.65 mmol) was dissolved in DCM (3 mL) and TFA (3 mL), and the reaction mixture was stirred at room temperature for 2 hours. The mixture was concentrated to give compound 32-4 (240 mg, yield: 91%) as a light yellow oil.

[0193] Step 4: At room temperature, a mixture of compound 31-4 (200 mg, 0.67 mmol), DMAP (8 mg, 0.07 mmol), NHS (115 mg, 1.00 mmol) and EDCI (128 mg, 0.67 mmol) in anhydrous DMSO (3 mL) was stirred for 1 hour. Compound 32-4 (120 mg, 0.26 mmol) and Et3N (0.483 mL, 3.35 mmol) were added to the mixture. The mixture was stirred at room temperature for 12 hours and purified by prep-HPLC (eluted with 60% acetonitrile aqueous solution, HCl conditions) to obtain compound 32 (55 mg, yield: 28%) as a white solid. 1 H NMR(400MHz, DMSO-d6)δ8.60(d,J=7.8Hz,1H),8.01-7.90(m,1H),7.79(d,J=7.8Hz,2H),7.67-7.58(m, 2H),7.31(d,J=7.8Hz,2H),7.01(d,J=7.8Hz,2H),6.34(s,1H),4.45(dd,J=9.3,5.5Hz,1H),4.03(q,J= 5.7Hz,2H),3.28(t,J=5.6Hz,2H),3.00(t,J=7.7Hz,2H),2.88(t,J=7.5Hz,2H),2.46(dd,J=19.7,7.7H z,4H),2.22-2.11(m,1H),2.07(t,J=7.4Hz,2H),2.04-1.94(m,1H),1.77(q,J=7.4Hz,2H).LCMS: m / z calculation C 32H 35 IN6O7:742.57; Obtained:743.3.[M+H] + . Embodiment 33 (S)-2-(4-(2-(2-amino-4-oxo-4,7-dihydro-3H-pyrrolo[2,3-d]pyrimidin-5-yl)ethyl)benzamido)-5-(4-((S)-2-(4-isobutylphenyl)propionyl)piperazin-1-yl)-5-oxopentanoic acid (33) Synthesis Scheme 33

[0194] Step 1: EDCI (3.7 g, 19.37 mmol) was added to a mixture of acid 8-1 (2.00 g, 9.69 mmol), amine 33-1 (2.70 g, 14.49 mmol) and DMAP (118 mg, 0.967 mmol) in DCM (20 mL), and the mixture was stirred at room temperature for 4 hours. The reaction mixture was diluted with DCM (50 mL), washed with 1N HCl (50 mL x 2) and brine (50 mL x 2). The organic layer was dried over anhydrous Na2SO4, filtered and concentrated to give compound 33-2 (3.62 g, crude product) as a white solid, which was used directly in the next step without further purification. LCMS: m / z calculated for C 22 H 34 N2O3: 374.53; obtained: 397.47.[M+Na] + .

[0195] Step 2: To a solution of compound 33-2 (3.62 g, crude product) in EtOAc (30 mL) was added a solution of 4N HCl in EtOAc (30 mL). The mixture was stirred at room temperature for 1 hour. The mixture was diluted with EtOAc (30 mL) and filtered. The precipitate was washed with EtOAc and dried to give compound 33-3 (2.7 g, yield after 2 steps: 89%) as a white solid. LCMS: m / z calculated for C 17 H 26 N2O: 274.41; Obtained: 275.90.[M+H] + .

[0196] Step 3: At 0°C, EDCI (3.12 g, 16.33 mmol) was added to a DCM (40 mL) solution of DMAP (200 mg, 1.64 mmol), TEA (1.75 g, 17.32 mmol), compound 33-3 (2.70 g, 8.68 mmol) and compound 31-1 (2.48 g, 8.17 mmol). After stirring at room temperature for 2 hours, the mixture was diluted with DCM (100 mL), washed with 1N HCl (50 mL) and brine (50 mL). The organic layer was dried over Na2SO4, filtered and concentrated. The crude product was purified by silica gel column (eluted with 50% EtOAc in petroleum ether) to give compound 33-4 (3.66 g, yield: 80%) as a white solid. LCMS: m / z calculated for C 31 H 49 N3O6:559.75; obtained:582.98.[M+Na] + .

[0197] Step 4: Compound 33-4 (2.88 g, 5.00 mmol) was dissolved in DCM (10 mL) and TFA (10 mL) and stirred at room temperature for 2 hours. The mixture was concentrated to give compound 33-5 (2.6 g, yield: 90%) as a light yellow oil. LCMS: m / z calculated C 22 H 33 N3O4:403.52; Obtained:404.95.[M+H] + .

[0198] Step 5: At room temperature, a mixture of compound 31-4 (300 mg, 1.00 mmol), DMAP (12 mg, 0.098 mmol), NHS (174 mg, 1.51 mmol) and EDCI (383 mg, 2.00 mmol) in anhydrous DMSO (3 mL) was stirred for 2 hours. After the NHS activated ester was completely formed, compound 33-5 (560 mg, 1.08 mmol) and Et3N (508 mg, 5.02 mmol) were added. At 30° C., the mixture was stirred for 12 hours and purified by prep-HPLC (eluted with 60% acetonitrile aqueous solution, TFA conditions) to obtain compound 33 (43 mg, yield: 4%) as a white solid. 1H NMR(400MHz,DMSO-d6 andD2O)δ7.75(dd,J=8.0,3.9Hz,2H),7.28(d,J=8.1Hz,2H),7.13(d,J=6.6Hz,2H),7.08(d,J= 7.6Hz,2H),6.37(s,1H),4.34(s,1H),4.05(q,J=6.7Hz,1H),3.58-3.48(m,4H),3.48-3.34(m,4 H),2.97(dd,J=9.3,6.2Hz,2H),2.86(dd,J=9.6,5.9Hz,2H),2.38(d,J=6.5Hz,4H),1.99(dt,J= 40.0, 6.8Hz, 2H), 1.84-1.71 (m, 1H), 1.26 (d, J = 6.6Hz, 3H), 0.81 (t, J = 6.1Hz, 6H). LCMS: m / z calculation C 37 H 45 N7O6: 683.81; Obtained: 684.65.[M+H] + . Embodiment 34 N2-(4-(2-(2-amino-4-oxo-4,7-dihydro-3H-pyrrolo[2,3-d]pyrimidin-5-yl)ethyl)benzoyl)-N5-(2-((S)-2-(4-isobutylphenyl)propionamido)ethyl)-L-glutamine (34) Synthesis Scheme 34

[0199] Step 1: EDCI (3.71 g, 19.42 mmol) was added to a mixture of acid 8-1 (2.00 g, 9.69 mmol), amine 9-1 (2.33 g, 14.54 mmol) and DMAP (238 mg, 1.95 mmol) in DCM (20 mL), and the mixture was stirred at room temperature for 4 hours. The reaction mixture was diluted with DCM (50 mL), washed with 1N HCl (50 mL x 2) and brine (50 mL x 2). The organic layer was dried over anhydrous Na2SO4, filtered and concentrated to give compound 34-1 (3.2 g, crude product) as a white solid, which was used directly in the next step without further purification. LCMS: m / z calculated for C 20 H 32 N2O3: 348.49; obtained: 397.47.[M+Na] + .

[0200] Step 2: To a solution of compound 34-1 (3.2 g, crude product) in EtOAc (30 mL) was added a solution of 4N HCl in EtOAc (30 mL), and the mixture was stirred at room temperature for 1 hour to completely form a white precipitate. The mixture was diluted with EtOAc (30 mL) and filtered. The precipitate was washed with EtOAc and dried to give compound 34-2 (1.9 g, yield after 2 steps: 68%) as a white solid. LCMS: m / z calculated for C15H24N2O: 248.37; obtained: 249.90. [M+H] + .

[0201] Step 3: At 0°C, EDCI (1.28 g, 6.70 mmol) was added to a solution of DMAP (82 mg, 0.672 mmol), TEA (680 mg, 6.73 mmol), compound 34-2 (1.0 g, 3.51 mmol) and compound 31-1 (1.01 g, 3.32 mmol) in DCM (20 mL). The reactants were stirred at room temperature for 2 hours, and the mixture was diluted with DCM (50 mL), washed with 1N HCl (50 mL) and brine (50 mL). The organic layer was dried over Na2SO4, filtered and concentrated. The crude product was purified by silica gel column (eluted with 50% EtOAc in petroleum ether) to give compound 34-3 (953 mg, yield: 53%) as a white solid. LCMS: m / z calculated for C 29 H 47 N3O6:533.71; obtained:556.98.[M+Na] + .

[0202] Step 4: Compound 34-3 (700 mg, 1.31 mmol) was dissolved in DCM (7 mL) and TFA (7 mL) and stirred at room temperature for 2 hours. The mixture was concentrated to give compound 34-4 (700 mg, yield: 90%) as a light yellow oil. LCMS: m / z calculated C 20 H 31 N3O4: 377.49; Obtained: 378.88.[M+H] + .

[0203] Step 5: At room temperature, a mixture of compound 31-4 (135 mg, 0.452 mmol), DMAP (5 mg, 0.0409 mmol), NHS (78 mg, 0.678 mmol) and EDCI (172 mg, 0.900 mmol) in anhydrous DMSO (3 mL) was stirred for 2 hours. After the NHS activated ester was completely formed, compound 34-4 (310 mg, 0.630 mmol) and Et3N (230 mg, 2.27 mmol) were added. At 30° C., the mixture was stirred for 12 hours and purified by prep-HPLC (eluted with 60% acetonitrile aqueous solution, TFA conditions) to obtain compound 34 (26 mg, yield: 6%) as a white solid. 1 H NMR(400MHz, DMSO-d6andD2O)δ7.81(dd,J=18.1,7.9Hz,2H),7.30(dd,J=11.5,7.9Hz,2H),7.1 9-7.15(m,2H),7.06-7.02(m,2H),6.36(s,1H),4.33(dd,J=10.2,4.6Hz,1H),3.14-3.00(m,4H ),2.99-2.94(m,2H),2.86(dd,J=9.3,5.8Hz,2H),2.37(d,J=7.1Hz,2H),2.18(t,J=7.5Hz,2H) ,2.14-1.86(m,2H),1.82-1.70(m,1H),1.28(d,J=6.9Hz,3H),0.84-0.79(m,6H).LCMS:m / z Calculate C 35 H 43 N7O6: 657.77; Obtained: 658.86.[M+H] + . Embodiment 35 trans-[Pt(DACH)(ox)(OH)(IPBA)](35, IPBA=4-(4-iodophenyl)butyric acid)(35) Synthesis Scheme 35

[0204] Step 1: Hydrogen peroxide (30%, 15 mL) was added dropwise to a suspension of oxaliplatin 35-1 (200 mg, 0.50 mmol) in water (5 mL). After addition, the reaction mixture was heated to 75 ° C and stirred for 5 hours. A clear solution was formed and cooled to room temperature. The resulting solution was concentrated. The residue was washed with EtOH and MTBE to obtain compound 35-2 (170 mg, yield: 78%) as a yellow solid.

[0205] Step 2: TEA (55 μL, 0.39 mmol) was added to a solution of acid 1-2 (114 mg, 0.39 mmol) and TBTU (127 mg, 0.39 mmol) in anhydrous DMSO (5 mL). The mixture was stirred vigorously at room temperature for 15 minutes. Compound 35-2 (170 mg, 0.39 mmol) was added and the reaction mixture was stirred at 60 ° C for 16 hours. The resulting reaction mixture was filtered to remove unreacted solids. The clear solution obtained by reverse phase flash chromatography purification (C18 column, eluted with 50% acetonitrile aqueous solution, neutral conditions). The desired component was lyophilized overnight to obtain compound 35 (50.8 mg, yield: 18%) as a white solid. 1 H NMR (400MHz, DMSO-d6) δ7.59(d,J=7.8Hz,2H),6.97(d,J=7.8Hz,2H),2.44(d,J=7.6Hz,2H ),2.15(d,J=7.5Hz,2H),2.06(t,J=17.4Hz,2H),1.68(t,J=7.5Hz,2H),1.56-0.99(m,8H). Embodiment 36 trans-[Pt(DACH)(ox)(IPBA)2](36, IPBA=4-(4-iodophenyl)butyric acid)(36) Synthesis Scheme 36

[0206] Step 1: A mixture of compound 1-2 (587 mg, 2.03 mmol), TBTU (650 mg, 2.02 mmol) and TEA (205 mg, 2.02 mmol) in DMF (5 mL) was stirred under nitrogen for 15 minutes at room temperature. Compound 35-2 (218 mg, 0.506 mmol) was added to the mixture in one go. The resulting reactant was stirred at 60 ° C for 16 hours, and the mixture was filtered to remove unreacted solids. The clear solution was directly purified by reverse phase flash chromatography (C18 column, acetonitrile and water, neutral conditions) to obtain compound 36 (60 mg, yield: 12%) as a white solid. 1H NMR(400MHz,DMSO-d6)δ7.60(dd,J=8.0,3.8Hz,4H),6.97(dd,J=8.2,3.8Hz,4H),2.47(s,4H),2 .23(q,J=6.6Hz,4H),2.10(d,J=12.9Hz,2H),1.77-1.62(m,4H),1.53-1.03(m,8H).LCMS:m / z Calculate C 28 H 34 I2N2O8Pt: 975.48; Obtained: 976.57 [M+H] + . Embodiment 37 N-((S)-1-(((R)-1-(6-(2-(2-(2-((S)-2-(4-isobutylphenyl)propionamido)ethoxy)ethoxy)ethyl)-4,8-dioxo-1,3,6,2-dioxazaborolan-2-yl)-3-methylbutyl)amino)-1-oxo-3-phenylpropan-2-yl)pyrazine-2-carboxamide (37) Synthesis Scheme 37

[0207] Step 1: To a solution of compound 37-1 (1.0 g, 4.02 mmol) in DMF (10 mL) was added NaHCO3 (3.38 g, 40.23 mmol), KI (669 mg, 4.03 mmol) and compound 9-2 (3.36 g, 20.11 mmol). The mixture was stirred at room temperature for 4 hours. After the reaction was completed, the mixture was partitioned between EtOAc (100 mL) and water (100 mL). The organic layer was washed with brine, dried over anhydrous Na2SO4 and concentrated. The residue was purified by silica gel column (eluted with 50% EtOAc in petroleum ether) to give compound 37-2 (1.14 g, yield: 67%). LCMS: calculated C 19 H 36 N2O8: 420.50; obtained: 443.85 [M+Na] + .

[0208] Step 2: A mixture of compound 37-2 (1.14 g, 2.71 mmol) in 4N HCl (EtOAc solution, 10 mL) was stirred at room temperature for 1.5 hours. After the reaction was completed, the mixture was concentrated to give compound 37-3 (1.36 g, crude product), which was used directly in the next step without further purification.

[0209] Step 3: At room temperature, a solution of compound 37-3 (1.36 g, crude product), compound 8-1 (670 mg, 3.24 mmol), DIPEA (525 mg, 4.06 mmol), HOBt (360 mg, 2.66 mmol) and EDCI (520 mg, 2.71 mmol) in DCM (10 mL) was stirred for 16 hours. After the reaction was completed, the mixture was diluted with DCM (100 mL) and washed with water (100 mL x2). The organic layer was dried over anhydrous Na2SO4, filtered and concentrated. The crude product was purified by reverse phase flash chromatography (C18 column, eluted with 65% acetonitrile aqueous solution, HCl conditions). The desired component was lyophilized to obtain compound 37-4 (948 mg, TFA salt, yield after 2 steps: 64%) as a white solid. LCMS: m / z calculated C 27 H 44 N2O7: 508.66; obtained: 531.73 [M+Na] + .

[0210] Step 4: At 0°C, NaOH (297 mg, 7.45 mmol) was added to a solution of compound 37-4 (945 mg, 1.73 mmol) in EtOH (9.5 mL) and H2O (3 mL). The reactant was stirred at room temperature for 2 hours. The mixture was concentrated and adjusted to pH = 2 with 1N HCl at 0°C. The aqueous mixture was purified by reverse phase flash chromatography (C18 column, eluted with 45% acetonitrile aqueous solution, HCl conditions). The desired fraction was lyophilized to give compound 37-5 (694 mg, yield: 82%) as a white solid. LCMS: m / z calculated for C 23 H 36 N2O7: 452.55; obtained: 453.52 [M+H] + .

[0211] Step 5: At 120° C., a mixture of compound 37-5 (100 mg, 0.204 mmol) and compound 9-7 (85 mg, 0.22 mmol) in toluene (3 mL) was stirred for 4 hours. After the reaction was completed, the mixture was concentrated. The crude product was purified by pre-TLC (acetonitrile: dichloromethane=1:3) to obtain compound 37 (97 mg, yield: 59%) as a white solid. 1HNMR(400MHz,DMSO-d6)δ9.05(s,1H),8.92(d,J=7.8Hz,1H),8.84(s,1H),8.71(s,1H),7.95(s,1H),7.37(d,J=9.3Hz, 1H),7.29-7.12(m,7H),7.03(d,J=6.9Hz,2H),4.66(d,J=6.2Hz,1H),4.28(d,J=17.6Hz,1H),4.02(dd,J=32.9,17.2Hz ,2H),3.68(t,J=18.8Hz,3H),3.46(s,3H),3.39-3.25(m,4H),3.16(s,2H),3.09-3.00(m,2H),2.37(s,2H),1.76(s,1H ),1.55(s,1H),1.41(t,J=12.4Hz,1H),1.27(d,J=6.3Hz,3H),1.23-1.16(m,1H),0.82(d,J=6.5Hz,12H).LCMS: m / z calculation C 42 H 57 BN6O9: 800.76; Obtained: 801.76 [M+H] + . Embodiment 38 (S)-4,11-diethyl-4-hydroxy-3,14-dioxo-3,4,12,14-tetrahydro-1H-pyrano[3',4':6,7]indolizino[1,2-b]quinolin-9-yl(S)-2-(4-(2-(methyl-d3)propyl-3,3,3-d3)phenyl)propanoate (38) Synthesis Scheme 38

[0212] Step 1: At room temperature, a mixture of compound 22-11 (30.0 mg, 0.141 mmol), EDCI (80.0 mg, 0.419 mmol) and HOBt (20.0 mg, 0.148 mmol) in anhydrous DMF (2 mL) was stirred for 5 minutes. Compound 1-1 (85 mg, 0.216 mmol) was added and the mixture was stirred at room temperature for 16 hours. The reaction mixture was distributed in EtOAc (30 mL) and water (20 mL). The organic layer was washed with brine, dried over anhydrous Na2SO4, filtered and concentrated. The crude product was purified by pre-TLC (5% MeOH in DCM) to obtain compound 38 (50 mg, yield: 60%) as an off-white solid. 1H NMR (500MHz, DMSO-d6) δ8.18(d,J=9.1Hz,1H),7.90(d,J=2.5Hz,1H),7.51(dd,J=9.1,2.5Hz ,1H),7.37(d,J=7.9Hz,2H),7.32(s,1H),7.20(d,J=7.8Hz,2H),5.43(s,2H),5.32(s,2H),4 .15 (q, J = 7.1 Hz, 1H), 3.16 (q, J = 7.6 Hz, 2H), 2.45 (d, J = 7.2 Hz, 2H), 1.85 (ddt, J = 28.9, 14.6, 7.2 Hz, 3H), 1.57 (d, J = 7.1 Hz, 3H), 1.27 (t, J = 7.6 Hz, 3H), 0.88 (t, J = 7.3 Hz, 3H). LCMS: m / z calculated for C 35 H 30 D6N2O6:586.72; Obtained:588.13[M+H] + . Example 39 Cellular IC50 of three tumor cell lines

[0213] Cell inhibition was determined in three assays: U87MG and A549, MC38. Cells were obtained, cultured in appropriate medium supplemented with 10% fetal bovine serum and 100 U / mL penicillin G sodium, and placed in a cell culture incubator (37°C, 5% CO2). Before testing, cells in the culture dish were washed with phosphate buffered saline and detached with trypsin. The cell suspension was diluted with culture medium and adjusted for cell number, and added to a 96-well cell plate. Cells were placed in the incubator overnight. In the T0 control plate, 100 μL of CellTiter-Glo reagent was added to the cells, equilibrated at room temperature for 10 minutes, and the chemiluminescence value was read using Envision.

[0214] In the test plate, the compound was dissolved in the corresponding solvent and diluted in a gradient. The diluted compound solution was added to the 96-well plate with cells. After incubation for 72 h, 100 μμL CellTiter-Glo reagent was added to the cells, equilibrated at room temperature for 10 minutes, and the chemiluminescence value was read using Envision. The IC50 value was calculated using the GraphPad Prism software package (Prism 6 for Windows, version 6.0, GraphPad Software Inc., San Diego, CA). The IC50 values ​​of the three cell assays were 50 As shown in Table 1. Table 1. IC50 Compound U87MG (IC50, nM) A549 (IC50, nM) MC38 (IC50, nM) 8 13.37693 207.81632 22.74152 16 7.266483 10.68657 15.94872 9-7(Valcade) 6.890381 9.36019 16.29071 1-1(SN-38) 13.58112 99.519661 21.24506 5-1 NA NA NA 8-1 #intersect #intersect >10000 16-2 #intersect #intersect #intersect A: <1μM; B: 1-10μM.C: >10μM Example 4. Chemical stability in PBS (pH 7.4)

[0215] The chemical stability analysis was performed according to the following steps. 1. Test compound spiking solution: 1 mM test compound spiking solution A: Add 10 μL of 10 mM test compound stock solution to 90 μL DMSO. 2. Add 396 μL of buffer to the tubes at different designated time points. Preheat the samples at 37°C for 10 minutes. 3. Add 4 μL of spike solution A to the well designated as 0 min (or 15, 45, 90, 120 min) containing 396 μL of buffer and start the countdown. 4. At each time point, add 1200 μL of ACN containing IS to the tube. 5. Centrifuge the sample at 10,000 rpm for 5 minutes, and then prepare 100 μL of the supernatant for LC-MS / MS analysis. Table 2. stability Example 41 Pharmacokinetics

[0216] Male CD-1 mice (Shanghai Jihui Experimental Animal Care Co., Ltd., 6-8 weeks old) were used to determine the pharmacokinetic parameters. The animals were placed under a 12-hour light / dark cycle. During the study, the animals had free access to food and water.

[0217] For intravenous injection, the compound was formulated into a solution with a dose volume of 5 mL / kg (in 5% DMSO + 10% Solutol HS15 + 85% (20% HP-β-CD aqueous solution)) and administered via the tail vein. For subcutaneous injection, the compound was formulated into a solution with a dose volume of 10 mL / kg (in 5% DMSO + 10% Solutol HS15 + 85% (20% HP-β-CD aqueous solution)) or a solution with a dose volume of 50 μL / mouse (in 0.5% MC + 1% Pluronic F68 aqueous solution) and administered via subcutaneous injection.

[0218] Semi-serial blood samples (approximately 110 μL) were taken from animals at the following time points: 0.083, 0.25, 0.5, 1, 2, 4, 8, and 24 h for the intravenous (IV) group and 0.5, 2, 4, 8, 24, 48, and 96 h for the subcutaneous (SC) group. After sampling, samples were kept on ice for no longer than 15 min and then centrifuged within 15 min (2000 g, 5 min, 4°C). Plasma was snap-frozen in dry ice and then transferred to a -70°C freezer for long-term storage until LC-MS / MS analysis.

[0219] Tissue collection was performed for the SC group at 0.5, 2, 4, 8, 24, 48, and 96 hours. After the animals were anesthetized and bled, tissue samples (including muscle and skin) were collected and weighed, then quickly frozen in liquid nitrogen and further stored at -70°C for a long time until LC-MS / MS analysis. Tissue samples were homogenized under freezing conditions.

[0220] PK parameters were generated from LC-MS / MS data using Phoenix WinNonlin 8.2 software. Table 3. Pharmacokinetic data

[0221] Applicants have described the present disclosure in preferred embodiments in conjunction with the accompanying drawings, wherein like numbers represent like or similar elements. References in this specification to "one embodiment," "an embodiment," or similar language indicate that a particular feature, structure, or characteristic described in conjunction with the embodiment is included in at least one embodiment of the present invention. Therefore, the appearance of the phrases "in one embodiment," "in an embodiment," and similar terms throughout this specification may, but do not necessarily, all refer to the same embodiment.

[0222] In one or more embodiments, the features, structures or characteristics disclosed by the applicant can be combined in any suitable manner. In the description herein, many specific details are listed to provide a comprehensive understanding of the embodiments of the present invention. However, those skilled in the relevant art will recognize that the applicant's composition and / or method can be implemented in the absence of one or more specific details, or with other methods, ingredients, materials, etc. In other cases, known structures, materials or operations are not shown or described in detail to avoid blurring aspects of the present disclosure.

[0223] In this specification and the appended claims, the singular forms "a," "an," and "the" include plural references unless the context clearly dictates otherwise.

[0224] Unless otherwise defined, all technical and scientific terms used in this application have the meanings commonly understood by those of ordinary skill in the art. Although any methods and materials similar or equivalent to the methods and materials described herein can also be used in practice or testing, only preferred methods and materials are described here. Except for the specific order disclosed, the methods described herein can be operated in any order that is logically possible. Incorporated by Reference

[0225] This application refers to and quotes other documentary materials, such as patents, patent applications, patent publications, journals, books, papers, and online content, and the entire contents of the above materials are incorporated into this application by reference. Any material or part thereof, that is, incorporated herein by reference, but conflicts with existing definitions, statements, or other public materials clearly set forth herein, is incorporated only if there is no conflict between the incorporated material and the disclosed material. In the event of a conflict, the conflict will be resolved from the perspective of being beneficial to this application, and the disclosure that is beneficial to this application will be used as a preferred embodiment. Equivalent

[0226] The above representative embodiments are intended to help explain the present invention, are not intended to limit the scope of the present invention, and should not be interpreted as limiting the scope of the present invention. In fact, except for what is shown and described in the application, the full content of this application, including the examples contained in the application and the citations to scientific and patent documents, makes it obvious to those skilled in the art that various modifications of the present invention and various further embodiments thereof. These embodiments contain important additional information, examples and guidance, which are applicable to the practice of various embodiments of the present invention and equivalents thereof.

Claims

1. A compound, characterized in that It has the structural formula (I): in, X is CHR or NR, R is H or alkyl, or a pharmaceutically acceptable form or isotopic derivative thereof.

2. The compound according to claim 1, characterized in that Selected from:

3. A compound, characterized in that It has the structural formula (II): or a pharmaceutically acceptable form or isotopic derivative thereof.

4. The compound according to claim 3, characterized in that Selected from:

5. A compound, characterized in that Has the following structural formula: or a pharmaceutically acceptable form or isotopic derivative thereof.

6. A compound, characterized in that It has the structural formula (III): wherein n is an integer selected from 2 to 8, or a pharmaceutically acceptable form or isotopic derivative thereof.

7. The compound according to claim 6, characterized in that Selected from:

8. A compound, characterized in that It has the structural formula (IV): wherein n is an integer selected from 2 to 10, or a pharmaceutically acceptable form or isotopic derivative thereof.

9. The compound according to claim 8, characterized in that Selected from:

10. A compound, characterized in that It has the structural formula (V): in, R 2 is H or P(=O)R2, R is an alkyl group, L is a single bond or a group selected from the following: k is an integer selected from 0 to 4, or a pharmaceutically acceptable form or isotopic derivative thereof.

11. The compound according to claim 10, characterized in that Selected from:

12. A compound, characterized in that It has the structural formula (VI): in, R 2 is H or P(=O)R2, R is an alkyl group, L is a single bond or a group selected from the following: k is an integer selected from 0 to 4, or a pharmaceutically acceptable form or isotopic derivative thereof.

13. The compound according to claim 12, characterized in that Has the following structure:

14. A compound, characterized in that Has the following structural formula: or a pharmaceutically acceptable form or isotopic derivative thereof.

15. A compound, characterized in that Has the following structural formula: or a pharmaceutically acceptable form or isotopic derivative thereof.

16. A compound, characterized in that Has the following structural formula: or a pharmaceutically acceptable form or isotopic derivative thereof.

17. A compound, characterized in that Has the following structural formula: or a pharmaceutically acceptable form or isotopic derivative thereof.

18. A compound, characterized in that Has the following structural formula: or a pharmaceutically acceptable form or isotopic derivative thereof.

19. A compound, characterized in that Has the following structural formula: or a pharmaceutically acceptable form or isotopic derivative thereof.

20. A pharmaceutical composition, characterized in that The composition comprises the compound according to any one of claims 1 to 19 and a pharmaceutically acceptable excipient or carrier, and a diluent.

21. The pharmaceutical composition according to claim 20, characterized in that Effectively treat or alleviate cancer or related diseases and disorders.

22. A unit dosage form, characterized in that Comprising the pharmaceutical composition of claim 20 or 21.

23. A method for treating or alleviating a disease or disorder, characterized in that: The method comprises administering a pharmaceutical composition to a subject in need thereof, wherein the pharmaceutical composition comprises a compound according to any one of claims 1 to 19 and a pharmaceutically acceptable excipient or carrier, and a diluent.

24. The method according to claim 23, characterized in that The disease or disorder is cancer or a disease or disorder related thereto.

25. An application, characterized in that, Use of the compound of any one of claims 1-19 to treat or alleviate a disease or disorder.

26. A use for preparing a drug for treating or alleviating a disease or disorder, characterized in that: The compound according to any one of claims 1 to 19 and a pharmaceutically acceptable excipient or carrier, diluent are used.

27. The use according to claim 25 or 26, characterized in that The disease or disorder is cancer or a disease or disorder related thereto.

Citation Information

Patent Citations

  • Novel aryloxyphenylpropanamines

    WO2007005643A2

  • Novel aryloxypropanamines

    WO2007005644A2

  • Novel pharmaceutical compounds

    WO2007016361A2

  • Novel benzo [d] [1,3]-dioxol derivatives

    WO2007016431A2